@NP	Combination of Olfactory Ensheathing Cells	1
@NP	Combination	1
@NP	Olfactory Ensheathing Cells	16
@NP	Local Versus Systemic cAMP Treatment	49
@NP	a Cervical Rubrospinal Tract	92
@NP	Injury The failure of CNS axons to regenerate following traumatic injury	121
@NP	Injury	121
@NP	The failure of CNS axons	129
@NP	The failure	129
@NP	CNS axons	144
@NP	traumatic injury	178
@NP	part	205
@NP	a growth-inhibitory environment in CNS	213
@NP	a growth-inhibitory environment	213
@NP	CNS	248
@NP	a weak intrinsic neuronal growth response	263
@NP	Olfactory ensheathing cell -LRB- OECs -RRB- transplants	306
@NP	Olfactory ensheathing cell	306
@NP	OECs	334
@NP	a favorable environment	381
@NP	axonal regeneration , remyelination , and functional recovery	415
@NP	axonal regeneration	415
@NP	remyelination	436
@NP	functional recovery	455
@NP	spinal cord injury	481
@NP	our previous experiments	513
@NP	OEC transplants	539
@NP	regeneration of rubrospinal axons	573
@NP	regeneration	573
@NP	rubrospinal axons	589
@NP	the site of a dorsolateral funiculus crush in rats	626
@NP	the site	626
@NP	a dorsolateral funiculus crush in rats	638
@NP	a dorsolateral funiculus crush	638
@NP	rats	672
@NP	Rubrospinal neurons	678
@NP	massive cell atrophy and limited expression of regeneration-associated genes	706
@NP	massive cell atrophy and limited expression	706
@NP	regeneration-associated genes	753
@NP	axotomy	789
@NP	the same injury model	804
@NP	we	827
@NP	the hypothesis	837
@NP	treatment	857
@NP	the red nucleus with cAMP	870
@NP	the red nucleus	870
@NP	cAMP	891
@NP	the intrinsic growth response	916
@NP	other neurons	949
@NP	rubrospinal regeneration in combination	977
@NP	rubrospinal regeneration	977
@NP	combination	1005
@NP	OEC transplants	1022
@NP	addition	1042
@NP	we	1052
@NP	a systemic increase of cAMP using the phosphodiesterase inhibitor rolipram	1064
@NP	a systemic increase	1064
@NP	cAMP using the phosphodiesterase inhibitor rolipram	1087
@NP	cAMP	1087
@NP	the phosphodiesterase inhibitor rolipram	1098
@NP	OECs	1140
@NP	cavity formation	1155
@NP	astrocytic hypertrophy and the retraction of the axotomized rubrospinal axons	1184
@NP	astrocytic hypertrophy	1184
@NP	the retraction of the axotomized rubrospinal axons	1211
@NP	the retraction	1211
@NP	the axotomized rubrospinal axons	1229
@NP	the overall lesion size	1284
@NP	OEC transplantation	1309
@NP	the thresholds	1337
@NP	thermal sensitivity of both forepaws	1356
@NP	thermal sensitivity	1356
@NP	both forepaws	1379
@NP	None of our treatments , alone or in combination ,	1394
@NP	None	1394
@NP	our treatments	1402
@NP	combination	1430
@NP	rubrospinal regeneration	1452
@NP	the lesion site	1485
@NP	the systemic elevation of cAMP with rolipram	1511
@NP	the systemic elevation	1511
@NP	cAMP with rolipram	1537
@NP	cAMP	1537
@NP	rolipram	1547
@NP	greater numbers of OECs and axonal density	1568
@NP	greater numbers	1568
@NP	OECs and axonal density	1587
@NP	OECs	1587
@NP	axonal density	1596
@NP	the graft	1618
@NP	motor performance	1641
@NP	a cylinder test in conjunction	1662
@NP	a cylinder test	1662
@NP	conjunction	1681
@NP	astrocytic hypertrophy	1744
@NP	Axons	1769
@NP	spinal cord injury in higher vertebrates	1814
@NP	spinal cord injury	1814
@NP	higher vertebrates	1836
@NP	This inability	1856
@NP	a weak neuronal response	1892
@NP	axotomy -LRB- Plunet et al. , 2002 ; Filbin , 2003 -RRB-	1920
@NP	axotomy	1920
@NP	Plunet et al. , 2002 ; Filbin , 2003	1929
@NP	Plunet	1929
@NP	et al. , 2002 ; Filbin , 2003	1936
@NP	et al. , 2002	1936
@NP	et al.	1936
@NP	2002	1944
@NP	Filbin , 2003	1950
@NP	Filbin	1950
@NP	2003	1958
@NP	the presence of axon growth inhibitors associated with myelin	1975
@NP	the presence	1975
@NP	axon growth inhibitors associated with myelin	1991
@NP	axon growth inhibitors	1991
@NP	the astroglial scar	2046
@NP	Bradbury and McMahon , 2006 ; Harel and Strittmatter , 2006 ; Yiu and He , 2006	2067
@NP	Bradbury and McMahon	2067
@NP	2006 ; Harel and Strittmatter , 2006 ; Yiu and He	2089
@NP	2006	2089
@NP	Harel and Strittmatter , 2006 ; Yiu and He	2095
@NP	Harel and Strittmatter	2095
@NP	2006	2119
@NP	Yiu	2125
@NP	He	2133
@NP	2006	2137
@NP	the optimal OEC purity	2750
@NP	tissue source	2774
@NP	age	2789
@NP	species of donor animal , and culture conditions	2797
@NP	species of donor animal	2797
@NP	species	2797
@NP	donor animal	2808
@NP	culture conditions	2826
@NP	reviews	2880
@NP	Harvey	2892
@NP	et al. , 2006	2899
@NP	et al.	2899
@NP	2006	2907
@NP	Barnett and Riddell , 2007	2913
@NP	Barnett and Riddell	2913
@NP	2007	2934
@NP	Franssen et al. , 2007	2940
@NP	Franssen	2940
@NP	et al. , 2007	2949
@NP	et al.	2949
@NP	2007	2957
@NP	Richter and Roskams , 2008	2963
@NP	Richter and Roskams	2963
@NP	2008	2984
@NP	example	2995
@NP	the efficacy of OECs	3004
@NP	the efficacy	3004
@NP	OECs	3020
@NP	changes	3025
@NP	the culture methods	3038
@NP	the number	3067
@NP	passages and tissue source	3081
@NP	Richter et al. , 2005 ; Au et al. , 2007	3109
@NP	Richter	3109
@NP	et al. , 2005 ; Au et al. , 2007	3117
@NP	et al. , 2005	3117
@NP	et al.	3117
@NP	2005	3125
@NP	Au et al. , 2007	3131
@NP	Au	3131
@NP	et al. , 2007	3134
@NP	et al.	3134
@NP	2007	3142
@NP	their greater accessibility	3160
@NP	OECs derived from nasal mucosa	3189
@NP	OECs	3189
@NP	nasal mucosa	3207
@NP	the favored source	3229
@NP	OECs	3251
@NP	autologous transplantation in humans -LRB- Lu et al. , 2001 , 2002 -RRB-	3260
@NP	autologous transplantation	3260
@NP	humans -LRB- Lu et al. , 2001 , 2002 -RRB-	3290
@NP	humans	3290
@NP	Lu	3298
@NP	et al. , 2001 , 2002	3301
@NP	et al.	3301
@NP	2001	3309
@NP	2002	3315
@NP	We	3322
@NP	lamina	3350
@NP	OECs	3372
@NP	several properties	3383
@NP	those of OECs derived from the olfactory bulb	3413
@NP	those	3413
@NP	OECs derived from the olfactory bulb	3422
@NP	OECs	3422
@NP	the olfactory bulb	3440
@NP	distinct differences	3475
@NP	transplantation	3513
@NP	the injured rat spinal cord	3534
@NP	Au and Roskams , 2003 ; Ramer et al. , 2004a ; Richter et al. , 2005	3563
@NP	Au and Roskams	3563
@NP	Au	3563
@NP	Roskams	3570
@NP	2003 ; Ramer et al.	3579
@NP	2003	3579
@NP	Ramer et al.	3585
@NP	Ramer	3585
@NP	et al.	3591
@NP	2004a ; Richter et al. , 2005	3599
@NP	2004a	3599
@NP	Richter et al. , 2005	3606
@NP	Richter	3606
@NP	et al. , 2005	3614
@NP	et al.	3614
@NP	2005	3622
@NP	rat rubrospinal axons	3644
@NP	OEC transplants	3694
@NP	the adult olfactory bulb	3723
@NP	the nasal mucosa	3764
@NP	newborn mice	3784
@NP	Ruitenberg et al. , 2003 ; Ramer et al. , 2004a ; Bretzner et al. , 2008	3798
@NP	Ruitenberg	3798
@NP	et al. , 2003 ; Ramer et al. , 2004a ; Bretzner et al. , 2008	3809
@NP	et al. , 2003	3809
@NP	et al.	3809
@NP	2003	3817
@NP	Ramer et al. , 2004a	3823
@NP	Ramer	3823
@NP	et al. , 2004a	3829
@NP	et al.	3829
@NP	2004a	3837
@NP	Bretzner et al. , 2008	3844
@NP	Bretzner	3844
@NP	et al. , 2008	3853
@NP	et al.	3853
@NP	2008	3861
@NP	We	3868
@NP	this failure	3889
@NP	part	3918
@NP	a weakness	3926
@NP	the intrinsic cell body response	3940
@NP	rubrospinal neurons -LRB- Tetzlaff et al. , 1991 ; Jenkins et al. , 1993 -RRB-	3976
@NP	rubrospinal neurons	3976
@NP	Tetzlaff	3997
@NP	et al. , 1991 ; Jenkins et al. , 1993	4006
@NP	et al.	4006
@NP	1991 ; Jenkins et al.	4014
@NP	1991	4014
@NP	Jenkins et al.	4020
@NP	Jenkins	4020
@NP	et al.	4028
@NP	1993	4036
@NP	such weakness	4047
@NP	other neurons of the central nervous system or dorsal root ganglions	4081
@NP	other neurons	4081
@NP	the central nervous system or dorsal root ganglions	4098
@NP	injury of their central axons -LRB- for review see Plunet et al. , 2002 -RRB-	4156
@NP	injury	4156
@NP	their central axons	4166
@NP	review	4191
@NP	Plunet	4202
@NP	et al. , 2002	4209
@NP	et al.	4209
@NP	2002	4217
@NP	Cell body treatment of the red nucleus with BDNF	4224
@NP	Cell body treatment	4224
@NP	the red nucleus with BDNF	4247
@NP	the red nucleus	4247
@NP	BDNF	4268
@NP	atrophy	4283
@NP	rubrospinal neurons , stimulated expression of regeneration-associated genes ,	4294
@NP	rubrospinal neurons	4294
@NP	expression of regeneration-associated genes	4326
@NP	expression	4326
@NP	regeneration-associated genes	4340
@NP	regeneration of rubrospinal axons	4384
@NP	regeneration	4384
@NP	rubrospinal axons	4400
@NP	peripheral nerve grafts	4423
@NP	a cervical spinal cord injury -LRB- Kobayashi et al. , 1997 -RRB-	4453
@NP	a cervical spinal cord injury	4453
@NP	Kobayashi	4484
@NP	et al. , 1997	4494
@NP	et al.	4494
@NP	1997	4502
@NP	this treatment	4519
@NP	1 year	4548
@NP	injury -LRB- Kwon et al. , 2002 -RRB-	4561
@NP	injury	4561
@NP	Kwon	4569
@NP	et al. , 2002	4574
@NP	et al.	4574
@NP	2002	4582
@NP	Treatment of dorsal root ganglions with brain-derived neurotrophic factor	4589
@NP	Treatment	4589
@NP	dorsal root ganglions with brain-derived neurotrophic factor	4602
@NP	dorsal root ganglions	4602
@NP	brain-derived neurotrophic factor	4629
@NP	BDNF	4664
@NP	the intracellular cAMP concentration -LRB- Cai et al. , 1999 -RRB-	4696
@NP	the intracellular cAMP concentration	4696
@NP	Cai	4734
@NP	et al. , 1999	4738
@NP	et al.	4738
@NP	1999	4746
@NP	pretreatment of these cells	4757
@NP	pretreatment	4757
@NP	these cells	4773
@NP	cAMP also enhanced their neurite outgrowth in vitro	4790
@NP	cAMP	4790
@NP	their neurite outgrowth	4809
@NP	Cai et al. , 1999 ; Neumann et al. , 2002 ; Qiu et al. , 2002	4843
@NP	Cai	4843
@NP	et al. , 1999 ; Neumann et al. , 2002 ; Qiu et al. , 2002	4847
@NP	et al. , 1999	4847
@NP	et al.	4847
@NP	1999	4855
@NP	Neumann et al. , 2002	4861
@NP	Neumann	4861
@NP	et al. , 2002	4869
@NP	et al.	4869
@NP	2002	4877
@NP	Qiu et al. , 2002	4883
@NP	Qiu	4883
@NP	et al. , 2002	4887
@NP	et al.	4887
@NP	2002	4895
@NP	vivo -LRB- Qiu et al. , 2002 -RRB- and their regeneration	4915
@NP	vivo -LRB- Qiu et al. , 2002 -RRB-	4915
@NP	vivo	4915
@NP	Qiu	4921
@NP	et al. , 2002	4925
@NP	et al.	4925
@NP	2002	4933
@NP	their regeneration	4943
@NP	cellular transplants	4970
@NP	the injured dorsal column -LRB- Lu et al. , 2004 -RRB-	4994
@NP	the injured dorsal column	4994
@NP	Lu	5021
@NP	et al. , 2004	5024
@NP	et al.	5024
@NP	2004	5032
@NP	acute systemic elevation of cAMP	5049
@NP	acute systemic elevation	5049
@NP	cAMP	5077
@NP	the inhibitory environment of the injured spinal cord	5095
@NP	the inhibitory environment	5095
@NP	the injured spinal cord	5125
@NP	some functional recovery	5162
@NP	cell transplantation -LRB- Nikulina et al. , 2004 ; Pearse et al. , 2004 -RRB-	5206
@NP	cell transplantation	5206
@NP	Nikulina	5228
@NP	et al. , 2004 ; Pearse et al. , 2004	5237
@NP	et al.	5237
@NP	2004 ; Pearse et al.	5245
@NP	2004	5245
@NP	Pearse et al.	5251
@NP	Pearse	5251
@NP	et al.	5258
@NP	2004	5266
@NP	we	5278
@NP	rubrospinal tract axons	5292
@NP	we	5325
@NP	the past 2 decades	5344
@NP	axonal regeneration	5379
@NP	part	5405
@NP	a weakness of the intrinsic cell body response of rubrospinal tract neurons	5417
@NP	a weakness	5417
@NP	the intrinsic cell body response of rubrospinal tract neurons	5431
@NP	the intrinsic cell body response	5431
@NP	rubrospinal tract neurons	5467
@NP	Tetzlaff	5494
@NP	et al. , 1991	5503
@NP	et al.	5503
@NP	1991	5511
@NP	Jenkins et al. , 1993	5517
@NP	Jenkins	5517
@NP	et al. , 1993	5525
@NP	et al.	5525
@NP	1993	5533
@NP	Kobayashi et al. , 1997	5539
@NP	Kobayashi	5539
@NP	et al. , 1997	5549
@NP	et al.	5549
@NP	1997	5557
@NP	Kwon et al. , 2002	5563
@NP	Kwon	5563
@NP	et al. , 2002	5568
@NP	et al.	5568
@NP	2002	5576
@NP	We	5583
@NP	dibutyryl cAMP	5602
@NP	dbcAMP	5618
@NP	the vicinity of the red nucleus	5644
@NP	the vicinity	5644
@NP	the red nucleus	5660
@NP	the axotomy-induced atrophy	5685
@NP	the expression of regeneration-associated genes , i.e. , GAP43 and Ta1-tubulin	5728
@NP	the expression	5728
@NP	regeneration-associated genes , i.e. , GAP43 and Ta1-tubulin	5746
@NP	regeneration-associated genes	5746
@NP	i.e.	5777
@NP	GAP43	5783
@NP	Ta1-tubulin	5793
@NP	we	5813
@NP	cAMP elevation	5839
@NP	the systemic level	5857
@NP	the cell body level of the red nucleus	5883
@NP	the cell body level	5883
@NP	the red nucleus	5906
@NP	regeneration of rubrospinal axons	5936
@NP	regeneration	5936
@NP	rubrospinal axons	5952
@NP	OEC transplants	5986
@NP	functional recovery of the forelimb following a cervical spinal cord injury	6021
@NP	functional recovery	6021
@NP	the forelimb following a cervical spinal cord injury	6044
@NP	the forelimb	6044
@NP	a cervical spinal cord injury	6067
@NP	this	6108
@NP	we	6114
@NP	transplant	6126
@NP	OECs	6140
@NP	the nasal mucosa of green fluorescent protein-expressing neonatal mouse	6158
@NP	the nasal mucosa	6158
@NP	green fluorescent protein-expressing neonatal mouse	6178
@NP	a systemic treatment	6235
@NP	a cell body treatment of the red nucleus elevating cAMP level for 2 weeks	6259
@NP	a cell body treatment	6259
@NP	the red nucleus elevating cAMP level for 2 weeks	6284
@NP	the red nucleus	6284
@NP	cAMP level for 2 weeks	6310
@NP	cAMP level	6310
@NP	2 weeks	6325
@NP	both combinatorial approaches	6343
@NP	regeneration of rubrospinal axons through and beyond engrafted OECs	6391
@NP	regeneration	6391
@NP	rubrospinal axons through and beyond engrafted OECs	6407
@NP	rubrospinal axons	6407
@NP	OECs	6454
@NP	the systemic elevation	6460
@NP	cAMP by rolipram infusion combined with OEC transplants	6486
@NP	cAMP	6486
@NP	rolipram infusion combined with OEC transplants	6494
@NP	rolipram infusion	6494
@NP	OEC transplants	6526
@NP	the numbers of OECs and axonal density	6552
@NP	the numbers	6552
@NP	OECs and axonal density	6567
@NP	OECs	6567
@NP	axonal density	6576
@NP	the graft	6598
@NP	motor recovery	6621
@NP	conjunction	6639
@NP	astrocytic hypertrophy rostral	6702
@NP	the lesion site	6736
@NP	MATERIALS AND METHODS Animal procedures	6754
@NP	MATERIALS	6754
@NP	METHODS Animal procedures	6768
@NP	accordance	6812
@NP	the guidelines of the Canadian Council for Animal Care	6828
@NP	the guidelines	6828
@NP	the Canadian Council for Animal Care	6846
@NP	the Canadian Council	6846
@NP	Animal Care	6871
@NP	the Animal Care Committee of the University of British Columbia	6904
@NP	the Animal Care Committee	6904
@NP	the University of British Columbia	6933
@NP	the University	6933
@NP	British Columbia	6951
@NP	Preparation of LP-OECs	6970
@NP	Preparation	6970
@NP	LP-OECs	6985
@NP	Green Fluorescent Protein Transgenic Mice	6998
@NP	The preparation of OECs	7040
@NP	The preparation	7040
@NP	OECs	7059
@NP	detailed elsewhere -LRB- Ramer et al. , 2004a ; Bretzner et al. , 2008 -RRB-	7086
@NP	detailed elsewhere	7086
@NP	detailed	7086
@NP	Ramer	7106
@NP	et al. , 2004a ; Bretzner et al. , 2008	7112
@NP	et al.	7112
@NP	2004a ; Bretzner et al.	7120
@NP	2004a	7120
@NP	Bretzner et al.	7127
@NP	Bretzner	7127
@NP	et al.	7136
@NP	2008	7144
@NP	brief	7154
@NP	postnatal day	7161
@NP	5 transgenic mice	7175
@NP	green fluorescent protein were sacrificed by decapitation	7204
@NP	green fluorescent protein	7204
@NP	decapitation	7249
@NP	the olfactory mucosa	7267
@NP	ice-cold DMEM/F12	7317
@NP	Au and Roskams , 2003 ; Ramer et al. , 2004a ; Richter et al. , 2005	7336
@NP	Au and Roskams	7336
@NP	Au	7336
@NP	Roskams	7343
@NP	2003 ; Ramer et al.	7352
@NP	2003	7352
@NP	Ramer et al.	7358
@NP	Ramer	7358
@NP	et al.	7364
@NP	2004a ; Richter et al. , 2005	7372
@NP	2004a	7372
@NP	Richter et al. , 2005	7379
@NP	Richter	7379
@NP	et al. , 2005	7387
@NP	et al.	7387
@NP	2005	7395
@NP	The entire olfactory mucosa , including turbinates and septum ,	7402
@NP	The entire olfactory mucosa	7402
@NP	turbinates and septum	7441
@NP	turbinates	7441
@NP	septum	7456
@NP	one pup	7483
@NP	0.6 mg/ml collagenase D -LRB- Roche Products , Indianapolis , IN -RRB-	7535
@NP	0.6 mg/ml collagenase D	7535
@NP	Roche Products , Indianapolis	7560
@NP	Roche Products	7560
@NP	Indianapolis	7576
@NP	50 µg/ml dispase I	7595
@NP	Roche Products	7615
@NP	15 lg/ml hyaluronidase -LRB- Sigma , St.	7632
@NP	15 lg/ml hyaluronidase	7632
@NP	Sigma	7656
@NP	St.	7663
@NP	Louis , MO -RRB-	7667
@NP	Louis	7667
@NP	0.5 mg/ml bovine serum albumin -LRB- MP Biomedicals , Irvine , CA -RRB-	7679
@NP	0.5 mg/ml bovine serum albumin	7679
@NP	MP Biomedicals	7711
@NP	Irvine	7727
@NP	CA	7735
@NP	200 U/ml DNase I -LRB- Sigma -RRB-	7744
@NP	200 U/ml DNase	7744
@NP	I -LRB- Sigma -RRB-	7759
@NP	I	7759
@NP	Sigma	7762
@NP	1 hr at 378C	7773
@NP	1 hr	7773
@NP	378C	7781
@NP	centrifugation and plating	7794
@NP	Initial plating in MEM-D-valine	7822
@NP	Initial plating	7822
@NP	MEM-D-valine	7841
@NP	10 % fetal bovine serum -LRB- FBS -RRB-	7855
@NP	10 % fetal bovine serum	7855
@NP	FBS	7879
@NP	100 U/ml penicillin/streptomycin -LRB- P/S -RRB-	7889
@NP	100 U/ml penicillin/streptomycin	7889
@NP	P/S	7923
@NP	a poly L-lysine substrate	7933
@NP	additional mitogens	7967
@NP	4	8000
@NP	5 days	8002
@NP	purification enrichment performed using anti-Thy1.1-mediated complement lysis	8018
@NP	purification enrichment	8018
@NP	anti-Thy1.1-mediated complement lysis	8058
@NP	the majority of contaminating fibroblasts	8106
@NP	the majority	8106
@NP	contaminating fibroblasts	8122
@NP	Cells	8149
@NP	DMEM/F -12 , 10 % FBS , and 100 U/ml P/S	8172
@NP	DMEM/F -12	8172
@NP	10 % FBS	8183
@NP	100 U/ml P/S	8196
@NP	an additional 4	8233
@NP	6 days	8249
@NP	they	8271
@NP	Thy1.1-mediated complement lysis	8300
@NP	the same media for an additional 24	8346
@NP	the same media	8346
@NP	an additional 24	8365
@NP	48 hr	8382
@NP	transplantation	8397
@NP	a subset of cells	8428
@NP	a subset	8428
@NP	cells	8440
@NP	plastic coverslips	8462
@NP	antigenic assessment	8495
@NP	the same time	8519
@NP	cells	8547
@NP	the cultures for transplantation	8558
@NP	the cultures	8558
@NP	transplantation	8575
@NP	They	8592
@NP	as at least 75 % double immunopositive	8611
@NP	as at least 75 %	8611
@NP	p75 and GFAP	8653
@NP	the fibroblast portion -LRB- assessed as fibronectin1/p75 -- -RRB-	8670
@NP	the fibroblast portion	8670
@NP	fibronectin1/p75 --	8706
@NP	fibronectin1/p75	8706
@NP	25 %	8740
@NP	these culture conditions	8750
@NP	density of plating media , composition of plating media , and plating substrate	8776
@NP	density	8776
@NP	media , composition of plating media	8795
@NP	media	8795
@NP	composition of plating media	8802
@NP	composition	8802
@NP	plating media	8817
@NP	substrate	8844
@NP	we	8856
@NP	OECs	8887
@NP	Schwann cells	8916
@NP	Richter and Roskams	8950
@NP	2008	8971
@NP	This percentage	8978
@NP	that in our previous reports	9021
@NP	that	9021
@NP	our previous reports	9029
@NP	the results	9087
@NP	this study	9102
@NP	a 50 % fibroblast portion	9127
@NP	axonal regeneration	9202
@NP	Li	9223
@NP	et al. , 1997 , 1998 , 2003	9226
@NP	et al.	9226
@NP	1997	9234
@NP	1998	9240
@NP	2003	9246
@NP	The focus of this study	9253
@NP	The focus	9253
@NP	this study	9266
@NP	the effect of systemic and local cotreatments	9281
@NP	the effect	9281
@NP	systemic and local cotreatments	9295
@NP	the promotion of rubrospinal regeneration	9331
@NP	the promotion	9331
@NP	rubrospinal regeneration	9348
@NP	LP-OECs	9374
@NP	a density of 5,600 cells/cm2	9397
@NP	a density	9397
@NP	5,600 cells/cm2	9410
@NP	T75 flasks for transplantation	9431
@NP	T75 flasks	9431
@NP	transplantation	9446
@NP	transplantation	9470
@NP	the cells from one T75 flask of LP-OECs	9487
@NP	the cells	9487
@NP	one T75 flask of LP-OECs	9502
@NP	one T75 flask	9502
@NP	LP-OECs	9519
@NP	0.25 % trypsin/1 % EDTA	9547
@NP	0.25 %	9547
@NP	trypsin/1 %	9553
@NP	PBS	9593
@NP	resuspension at a concentration of 100,000 -- 120,000 cells/µl in DMEM/F -12	9601
@NP	resuspension at a concentration of 100,000	9601
@NP	resuspension	9601
@NP	a concentration of 100,000	9617
@NP	a concentration	9617
@NP	100,000	9636
@NP	120,000 cells/µl in DMEM/F -12	9644
@NP	120,000 cells/µl	9644
@NP	DMEM/F -12	9664
@NP	The total time from dissection to transplantation	9675
@NP	The total time	9675
@NP	dissection to transplantation	9695
@NP	dissection	9695
@NP	transplantation	9709
@NP	11 to 14 days	9737
@NP	initial experiments using freshly prepared OECs	9769
@NP	initial experiments	9769
@NP	freshly prepared OECs	9795
@NP	maintenance of phenotype	9827
@NP	maintenance	9827
@NP	phenotype	9842
@NP	cryopreservation	9858
@NP	cells -LRB- Ramer et al. , 2004a ; Bretzner et al. , 2008 -RRB-	9878
@NP	cells	9878
@NP	Ramer	9885
@NP	et al. , 2004a ; Bretzner et al. , 2008	9891
@NP	et al.	9891
@NP	2004a ; Bretzner et al.	9899
@NP	2004a	9899
@NP	Bretzner et al.	9906
@NP	Bretzner	9906
@NP	et al.	9915
@NP	2008	9923
@NP	we	9930
@NP	fresh OECs as well as cryopreserved cells	9938
@NP	fresh OECs	9938
@NP	cryopreserved cells	9960
@NP	the same batch in successive transplantations	9985
@NP	the same batch	9985
@NP	successive transplantations	10003
@NP	Spinal Cord Injury and Treatments	10032
@NP	Spinal Cord Injury	10032
@NP	Treatments	10055
@NP	total 47	10069
@NP	adult male Sprague-Dawley rats -LRB- 300 -- 400 g -RRB-	10078
@NP	adult male Sprague-Dawley rats	10078
@NP	300 -- 400 g	10110
@NP	300	10110
@NP	400 g	10114
@NP	this experiment	10135
@NP	Two groups from the current study -LRB- vehicle-DMEM and vehicle-OEC -RRB-	10152
@NP	Two groups	10152
@NP	the current study -LRB- vehicle-DMEM and vehicle-OEC -RRB-	10168
@NP	the current study	10168
@NP	vehicle-DMEM and vehicle-OEC	10187
@NP	vehicle-DMEM	10187
@NP	vehicle-OEC	10204
@NP	a study	10250
@NP	axonal regeneration and functional recovery	10268
@NP	axonal regeneration	10268
@NP	functional recovery	10292
@NP	OEC transplants in combination	10315
@NP	OEC transplants	10315
@NP	combination	10334
@NP	cell body treatment	10351
@NP	the red nucleus infusing BDNF -LRB- Bretzner et al. , 2008 -RRB-	10374
@NP	the red nucleus infusing BDNF	10374
@NP	Bretzner	10405
@NP	et al. , 2008	10414
@NP	et al.	10414
@NP	2008	10422
@NP	studies	10434
@NP	parallel	10460
@NP	identical conditions	10475
@NP	All rats	10497
@NP	cyclosporine A	10533
@NP	10 mg/kg	10549
@NP	day , i.p. ; Novartis Pharmaceuticals , Mississauga , Ontario , Canada	10562
@NP	day , i.p.	10562
@NP	day	10562
@NP	Novartis Pharmaceuticals , Mississauga , Ontario , Canada	10573
@NP	2 days	10629
@NP	surgery and each day	10643
@NP	surgery	10643
@NP	each day	10655
@NP	the duration of the experiment	10668
@NP	the duration	10668
@NP	the experiment	10684
@NP	Information Figure 1 and Table I	10715
@NP	Information Figure 1	10715
@NP	Information Figure	10715
@NP	1	10734
@NP	Table I	10740
@NP	Table	10740
@NP	I	10746
@NP	the experimental design and more details	10752
@NP	the experimental design	10752
@NP	more details	10780
@NP	We	10794
@NP	the treatment with cyclosporine A	10818
@NP	the treatment	10818
@NP	cyclosporine A	10837
@NP	cell death	10873
@NP	cyclosporine	10896
@NP	an inhibitor	10912
@NP	the mitochondrial permeability pore and neuroprotective	10928
@NP	the injured spinal cord -LRB- Halestrap et al. , 1997 -RRB-	10987
@NP	the injured spinal cord	10987
@NP	Halestrap	11012
@NP	et al. , 1997	11022
@NP	et al.	11022
@NP	1997	11030
@NP	we	11046
@NP	all groups	11057
@NP	this drug	11073
@NP	this effect	11084
@NP	unknown synergic effects with some of the treatments	11111
@NP	unknown synergic effects	11111
@NP	some of the treatments	11141
@NP	some	11141
@NP	the treatments	11149
@NP	Spinal cord injury .	11165
@NP	Spinal cord	11165
@NP	injury	11177
@NP	Dorsolateral funiculus	11185
@NP	Ramer et al. , 2004a ; Richter et al. , 2005 ; Bretzner et al. , 2008	11245
@NP	Ramer	11245
@NP	et al. , 2004a ; Richter et al. , 2005 ; Bretzner et al. , 2008	11251
@NP	et al. , 2004a	11251
@NP	et al.	11251
@NP	2004a	11259
@NP	Richter et al. , 2005	11266
@NP	Richter	11266
@NP	et al. , 2005	11274
@NP	et al.	11274
@NP	2005	11282
@NP	Bretzner et al. , 2008	11288
@NP	Bretzner	11288
@NP	et al. , 2008	11297
@NP	et al.	11297
@NP	2008	11305
@NP	Rats	11312
@NP	a mixture	11340
@NP	ketamine hydrochloride	11353
@NP	70 mg/kg , i.p. ; Bimeda-MTC , Cambridge , Ontario , Canada	11377
@NP	70 mg/kg , i.p.	11377
@NP	70 mg/kg	11377
@NP	Bimeda-MTC , Cambridge , Ontario , Canada	11393
@NP	xylazine hydrochloride	11437
@NP	10 mg/kg i.p. ; Bayer Inc. , Etobicoke , Ontario , Canada	11461
@NP	10 mg/kg i.p.	11461
@NP	10 mg/kg	11461
@NP	Bayer Inc. , Etobicoke , Ontario , Canada	11476
@NP	a laminectomy	11521
@NP	the left side	11552
@NP	the fourth and fifth cervical segments	11576
@NP	the fourth	11576
@NP	fifth cervical segments	11591
@NP	The dura	11616
@NP	microscissors	11638
@NP	the dorsolateral funiculus , which includes the rubrospinal tract	11662
@NP	the dorsolateral funiculus	11662
@NP	the rubrospinal tract	11705
@NP	The dorsolateral funiculus	11728
@NP	20 sec with a custom-designed fine surgical forceps	11771
@NP	20 sec	11771
@NP	a custom-designed fine surgical forceps	11783
@NP	a depth of 2 mm	11826
@NP	a depth	11826
@NP	2 mm	11837
@NP	the surface	11847
@NP	these forceps	11868
@NP	`` shoulders ''	11887
@NP	the blades	11914
@NP	a width of 0.2 mm and length of 2 mm	11928
@NP	a width of 0.2 mm	11928
@NP	a width	11928
@NP	0.2 mm	11939
@NP	length of 2 mm	11950
@NP	length	11950
@NP	2 mm	11960
@NP	it	11967
@NP	them	11992
@NP	a depth of 2 mm with good accuracy	12000
@NP	a depth	12000
@NP	2 mm with good accuracy	12011
@NP	2 mm	12011
@NP	good accuracy	12021
@NP	this dorsolateral funiculus crush lesion	12043
@NP	one animal	12114
@NP	another -LRB- Plunet et al. , 2008 -RRB-	12128
@NP	another	12128
@NP	Plunet	12137
@NP	et al. , 2008	12144
@NP	et al.	12144
@NP	2008	12152
@NP	us	12168
@NP	neuroanatomical changes	12182
@NP	spinal cord injury and the efficacy of various treatments	12216
@NP	spinal cord injury	12216
@NP	the efficacy of various treatments	12239
@NP	the efficacy	12239
@NP	various treatments	12255
@NP	Cell transplant .	12275
@NP	Cell	12275
@NP	transplant	12280
@NP	Lamina propria-derived OECs -LRB- LPOEC -RRB-	12292
@NP	Lamina propria-derived OECs	12292
@NP	LPOEC	12321
@NP	the spinal cord	12351
@NP	Ramer	12392
@NP	et al. , 2004a ; Richter et al. , 2005	12398
@NP	et al.	12398
@NP	2004a ; Richter et al.	12406
@NP	2004a	12406
@NP	Richter et al.	12413
@NP	Richter	12413
@NP	et al.	12421
@NP	2005	12429
@NP	LP-OEC slurries in DMEM/F -12	12436
@NP	LP-OEC slurries	12436
@NP	DMEM/F -12	12455
@NP	a pulled glass pipette with a diameter of 60	12481
@NP	a pulled glass pipette	12481
@NP	a diameter of 60	12509
@NP	a diameter	12509
@NP	60	12523
@NP	80 lm attached to a Hamilton syringe	12526
@NP	80 lm	12526
@NP	a Hamilton syringe	12544
@NP	OECs	12564
@NP	1 mm rostral and caudal	12604
@NP	1 mm rostral	12604
@NP	caudal	12621
@NP	the lesion site	12631
@NP	the suspension	12657
@NP	these two points	12688
@NP	A total of 1.5 µl of cell slurry	12706
@NP	A total	12706
@NP	1.5 µl of cell slurry	12717
@NP	1.5 µl	12717
@NP	cell slurry	12727
@NP	each rat	12761
@NP	a total of 150,000	12779
@NP	a total	12779
@NP	150,000	12790
@NP	180,000 cells	12798
@NP	Control animals	12813
@NP	the same volume of DMEM	12838
@NP	the same volume	12838
@NP	DMEM	12857
@NP	F-12	12863
@NP	the same sites	12880
@NP	the same rate	12898
@NP	The glass pipette	12913
@NP	place for 5 min	12943
@NP	place	12943
@NP	5 min	12953
@NP	each injection	12965
@NP	cells	12995
@NP	the spinal cord	13013
@NP	the syringe	13057
@NP	injection	13076
@NP	the pipette	13087
@NP	the muscle	13123
@NP	the skin	13152
@NP	wound clips	13173
@NP	Cell body treatment of the red nucleus infusing cAMP .	13186
@NP	Cell body treatment of the red nucleus	13186
@NP	Cell body treatment	13186
@NP	the red nucleus	13209
@NP	cAMP	13234
@NP	Dibutyryl cyclic adenosine monophosphate -LRB- dbcAMP -RRB- or vehicle	13240
@NP	Dibutyryl cyclic adenosine monophosphate -LRB- dbcAMP -RRB-	13240
@NP	Dibutyryl	13240
@NP	cyclic adenosine monophosphate -LRB- dbcAMP -RRB-	13250
@NP	cyclic adenosine monophosphate	13250
@NP	dbcAMP	13282
@NP	vehicle	13293
@NP	2 weeks	13317
@NP	a cannula	13329
@NP	the vicinity of the red nucleus	13363
@NP	the vicinity	13363
@NP	the red nucleus	13379
@NP	Kobayashi et al. , 1997 ; Kwon et al. , 2002 ; Bretzner et al. , 2008	13421
@NP	Kobayashi	13421
@NP	et al. , 1997 ; Kwon et al. , 2002 ; Bretzner et al. , 2008	13431
@NP	et al. , 1997	13431
@NP	et al.	13431
@NP	1997	13439
@NP	Kwon et al. , 2002	13445
@NP	Kwon	13445
@NP	et al. , 2002	13450
@NP	et al.	13450
@NP	2002	13458
@NP	Bretzner et al. , 2008	13464
@NP	Bretzner	13464
@NP	et al. , 2008	13473
@NP	et al.	13473
@NP	2008	13481
@NP	brief	13491
@NP	cell transplantation	13504
@NP	a 28-gauge cannula	13526
@NP	silastic tubing	13558
@NP	an osmotic minipump	13577
@NP	Alzet no. 2001 , 1 µl/hr ; Alzet , Palo Alto , CA	13598
@NP	Alzet no. 2001	13598
@NP	Alzet	13598
@NP	2001	13608
@NP	1 µl/hr ; Alzet	13614
@NP	1 µl/hr	13614
@NP	Alzet	13623
@NP	Palo Alto , CA	13630
@NP	Palo Alto	13630
@NP	CA	13641
@NP	stereotaxically 6.3 mm posterior	13658
@NP	6.3	13674
@NP	Bregma , 1.7 mm lateral -LRB- right -RRB- of midline	13694
@NP	Bregma	13694
@NP	1.7 mm lateral -LRB- right -RRB- of midline	13702
@NP	1.7 mm lateral -LRB- right -RRB-	13702
@NP	1.7 mm lateral	13702
@NP	right	13718
@NP	midline	13728
@NP	6.5 mm	13741
@NP	the dura	13758
@NP	Animals treated with cAMP	13768
@NP	Animals	13768
@NP	cAMP	13789
@NP	0.5 µg/µl/hr of cAMP -LRB- Calbiochem , La Jolla , CA -RRB-	13803
@NP	0.5 µg/µl/hr	13803
@NP	cAMP -LRB- Calbiochem , La Jolla , CA -RRB-	13819
@NP	cAMP	13819
@NP	Calbiochem	13825
@NP	La Jolla	13837
@NP	CA	13847
@NP	a vehicle solution of 20 mM sterile PBS and 100 units of penicillin/streptomycin	13854
@NP	a vehicle solution of 20 mM sterile PBS	13854
@NP	a vehicle solution	13854
@NP	20 mM sterile PBS	13876
@NP	20 mM	13876
@NP	100 units of penicillin/streptomycin	13898
@NP	100 units	13898
@NP	penicillin/streptomycin	13911
@NP	Animals treated with vehicle	13936
@NP	Animals	13936
@NP	vehicle	13957
@NP	the vehicle solution	13974
@NP	insertion	14008
@NP	the cannula and insertion of the miniosmotic pump under the skin of the neck	14021
@NP	the cannula and insertion	14021
@NP	the miniosmotic pump under the skin of the neck	14050
@NP	the miniosmotic pump	14050
@NP	the skin of the neck	14077
@NP	the skin	14077
@NP	the neck	14089
@NP	the skin	14099
@NP	wound clips	14124
@NP	Systemic treatment infusing rolipram .	14137
@NP	Systemic treatment	14137
@NP	rolipram	14165
@NP	Rolipram	14175
@NP	an inhibitor	14187
@NP	phosphodiesterase	14203
@NP	hydrolysis of cAMP	14235
@NP	hydrolysis	14235
@NP	cAMP	14249
@NP	accumulation of cAMP	14267
@NP	accumulation	14267
@NP	cAMP	14283
@NP	Rolipram or vehicle	14289
@NP	Rolipram	14289
@NP	vehicle	14301
@NP	the level of the left hindlimb	14339
@NP	the level	14339
@NP	the left hindlimb	14352
@NP	2 weeks	14374
@NP	a silicon tube	14386
@NP	an osmotic pump -LRB- Alzet no. 2ML1 , 10 µl/hr ; Alzet -RRB-	14414
@NP	an osmotic pump	14414
@NP	Alzet no. 2ML1 , 10 µl/hr ; Alzet	14431
@NP	Alzet no. 2ML1	14431
@NP	10 µl/hr ; Alzet	14447
@NP	10 µl/hr	14447
@NP	Alzet	14457
@NP	Pumps	14465
@NP	the end of each week	14487
@NP	the end	14487
@NP	each week	14498
@NP	the end of the 14 days	14523
@NP	the end	14523
@NP	the 14 days	14534
@NP	Animals treated with rolipram	14547
@NP	Animals	14547
@NP	rolipram	14568
@NP	0.4 µmol/kg/h of rolipram -LRB- Sigma -RRB-	14586
@NP	0.4 µmol/kg/h	14586
@NP	rolipram -LRB- Sigma -RRB-	14603
@NP	rolipram	14603
@NP	Sigma	14613
@NP	a vehicle solution of 20 mM sterile PBS and 16 % DMSO	14623
@NP	a vehicle solution	14623
@NP	20 mM sterile PBS and 16 % DMSO	14645
@NP	20 mM sterile PBS	14645
@NP	20 mM	14645
@NP	16 % DMSO	14667
@NP	Animals treated with vehicle	14677
@NP	Animals	14677
@NP	vehicle	14698
@NP	the vehicle solution	14715
@NP	insertion of the osmotic pump	14749
@NP	insertion	14749
@NP	the osmotic pump	14762
@NP	the skin	14780
@NP	wound clips	14805
@NP	Behavioral Testing Cylinder test .	14818
@NP	Behavioral Testing Cylinder	14818
@NP	test	14846
@NP	The forelimb usage	14852
@NP	a clear plexiglas cylinder -LRB- 20 cm in diameter and 30 cm high -RRB-	14889
@NP	a clear plexiglas cylinder	14889
@NP	20 cm in diameter and 30 cm	14917
@NP	20 cm	14917
@NP	diameter and 30 cm	14926
@NP	diameter	14926
@NP	30 cm	14939
@NP	5 min -LRB- Liu et al. , 1999 ; Schallert et al. , 2000 -RRB-	14955
@NP	5 min	14955
@NP	Liu	14962
@NP	et al. , 1999 ; Schallert et al. , 2000	14966
@NP	et al.	14966
@NP	1999 ; Schallert et al.	14974
@NP	1999	14974
@NP	Schallert et al.	14980
@NP	Schallert	14980
@NP	et al.	14990
@NP	2000	14998
@NP	The cylinder	15005
@NP	rats	15029
@NP	their forelimbs	15041
@NP	vertical exploration	15061
@NP	A mirror	15083
@NP	the cylinder	15110
@NP	scoring of movements from all viewpoints	15132
@NP	scoring	15132
@NP	movements from all viewpoints	15143
@NP	movements	15143
@NP	all viewpoints	15158
@NP	The behavior	15174
@NP	frame	15198
@NP	frame	15207
@NP	a later time point	15216
@NP	a blinded rater	15238
@NP	The forelimb use	15255
@NP	independent use of the left injured forelimb	15286
@NP	independent use	15286
@NP	the left injured forelimb	15305
@NP	independent use of the right forelimb	15332
@NP	independent use	15332
@NP	the right forelimb	15351
@NP	concomitant use of	15375
@NP	concomitant use	15375
@NP	forelimbs for contacting the wall of the cylinder during a full rear	15399
@NP	forelimbs	15399
@NP	the wall of the cylinder	15424
@NP	the wall	15424
@NP	the cylinder	15436
@NP	a full rear	15456
@NP	A minimum of 15 rears	15469
@NP	A minimum	15469
@NP	15 rears	15482
@NP	a more accurate use of the left forelimb	15512
@NP	a more accurate use	15512
@NP	the left forelimb	15535
@NP	the score	15554
@NP	a percentage use	15581
@NP	the `` left and both	15601
@NP	the `` left	15601
@NP	forelimbs relative to the total number of left , right , and both forelimb use	15623
@NP	forelimbs	15623
@NP	the total number of left , right , and both forelimb use	15645
@NP	the total number of left	15645
@NP	the total number	15645
@NP	both forelimb use	15682
@NP	Food-pellet-reaching task .	15701
@NP	The food-pellet-reaching task	15728
@NP	Whishaw 's test -LRB- Whishaw et al. , 1993 -RRB-	15775
@NP	Whishaw 's test	15775
@NP	Whishaw 's	15775
@NP	Whishaw	15791
@NP	et al. , 1993	15799
@NP	et al.	15799
@NP	1993	15807
@NP	the simplified	15818
@NP	Chan et al. , 2005	15865
@NP	Chan	15865
@NP	et al.	15870
@NP	2005	15878
@NP	brief	15888
@NP	the rats	15895
@NP	injury	15924
@NP	a 1-cm opening for a food pellet placed in a dimple 2 cm away	15948
@NP	a 1-cm opening	15948
@NP	a food pellet placed in a dimple 2 cm away	15967
@NP	a food pellet	15967
@NP	a dimple 2 cm away	15991
@NP	a dimple	15991
@NP	2 cm	16000
@NP	The animals	16011
@NP	the back of the box	16038
@NP	the back	16038
@NP	the box	16050
@NP	each reach and position itself for every reach	16064
@NP	each reach and position	16064
@NP	every reach	16099
@NP	The behavior	16112
@NP	a 10-point scale	16139
@NP	the execution of sequential aspects	16167
@NP	the execution	16167
@NP	sequential aspects	16184
@NP	score 3	16217
@NP	score 5	16237
@NP	score 7	16263
@NP	a food pellet	16272
@NP	details	16291
@NP	Chan	16303
@NP	et al. , 2005	16308
@NP	et al.	16308
@NP	2005	16316
@NP	the food-pellet-reaching task	16334
@NP	any influences	16379
@NP	other behavioral tests	16397
@NP	all rats	16421
@NP	week	16451
@NP	the night preceding the testing day	16459
@NP	the night	16459
@NP	the testing day	16479
@NP	Sensory tests	16496
@NP	Sensory testing	16511
@NP	rats	16549
@NP	allodynia	16570
@NP	the affected paw	16603
@NP	a motor behavior test , e.g. , the cylinder test	16623
@NP	a motor behavior test	16623
@NP	e.g. , the cylinder test	16646
@NP	e.g.	16646
@NP	the cylinder test	16652
@NP	The sensory testing	16671
@NP	Ramer et al. , 2004b ; Bretzner et al. , 2008	16720
@NP	Ramer	16720
@NP	et al. , 2004b ; Bretzner et al. , 2008	16726
@NP	et al. , 2004b	16726
@NP	et al.	16726
@NP	2004b	16734
@NP	Bretzner et al. , 2008	16741
@NP	Bretzner	16741
@NP	et al. , 2008	16750
@NP	et al.	16750
@NP	2008	16758
@NP	The thermal threshold of forepaws	16765
@NP	The thermal threshold	16765
@NP	forepaws	16790
@NP	the plantar tester -LRB- Ugo Basile , Italy -RRB-	16821
@NP	the plantar tester	16821
@NP	Ugo Basile	16841
@NP	Italy	16853
@NP	Rats	16861
@NP	a raised cage with a wire mesh floor over a moveable infrared generator	16881
@NP	a raised cage	16881
@NP	a wire mesh floor over a moveable infrared generator	16900
@NP	a wire mesh floor	16900
@NP	a moveable infrared generator	16923
@NP	The infrared source	16954
@NP	The	16954
@NP	source	16967
@NP	the center of the palm of the forepaw	16995
@NP	the center	16995
@NP	the palm of the forepaw	17009
@NP	the palm	17009
@NP	the forepaw	17021
@NP	The time from stimulus onset to withdrawal	17034
@NP	The time	17034
@NP	stimulus onset to withdrawal	17048
@NP	stimulus onset	17048
@NP	withdrawal	17066
@NP	both forepaws	17094
@NP	The latency of withdraw	17109
@NP	The latency	17109
@NP	both forepaws	17150
@NP	Rats	17165
@NP	weekly two or three times for each paw	17182
@NP	weekly two or three times	17182
@NP	each paw	17212
@NP	2	17225
@NP	3 weeks before injury	17227
@NP	3 weeks	17227
@NP	injury	17242
@NP	a control baseline	17259
@NP	any training/adaptation effects	17294
@NP	the postinjury period	17333
@NP	4 weeks after injury and treatment	17368
@NP	4 weeks	17368
@NP	injury and treatment	17382
@NP	Baseline behavior	17404
@NP	surgery	17442
@NP	all animals	17455
@NP	4 weeks	17490
@NP	injury and treatment	17504
@NP	The observer	17526
@NP	the treatment given	17554
@NP	the treatment	17554
@NP	Rubrospinal Axons	17586
@NP	Immunocytochemistry Anterograde	17608
@NP	rubrospinal axons	17651
@NP	Five weeks	17670
@NP	spinal cord injury and treatment	17687
@NP	spinal cord injury	17687
@NP	treatment	17710
@NP	rats	17721
@NP	a mixture	17749
@NP	ketamine hydrochloride	17762
@NP	70 mg / kg , i.p. ; Bimeda-MTC	17786
@NP	70 mg / kg , i.p. ;	17786
@NP	70 mg	17786
@NP	kg	17793
@NP	Bimeda-MTC	17803
@NP	xylazine hydrochloride	17819
@NP	10 mg	17843
@NP	10	17843
@NP	mg	17846
@NP	kg i.p. ; Bayer Inc.	17850
@NP	kg i.p.	17850
@NP	kg	17850
@NP	Bayer Inc.	17859
@NP	Bayer	17859
@NP	Inc.	17865
@NP	a Kopf stereotaxic frame	17885
@NP	dextran amine	17924
@NP	BDA ; 10,000 kDa molecular mass	17939
@NP	BDA	17939
@NP	10,000 kDa molecular mass	17944
@NP	10,000 kDa	17944
@NP	molecular mass	17955
@NP	10 % in sterile water	17971
@NP	10 %	17971
@NP	sterile water	17978
@NP	Molecular Probes	17993
@NP	Eugene , OR	18011
@NP	Eugene	18011
@NP	OR	18019
@NP	the red nucleus	18057
@NP	a rate of 80 nl	18076
@NP	a rate	18076
@NP	80 nl	18086
@NP	min	18093
@NP	a pulled glass pipette -LRB- diameter of 20 µm -RRB- glued to a Hamilton syringe	18106
@NP	a pulled glass pipette -LRB- diameter of 20 µm -RRB-	18106
@NP	a pulled glass pipette	18106
@NP	diameter of 20 µm	18130
@NP	diameter	18130
@NP	20 µm	18142
@NP	a Hamilton syringe	18158
@NP	Coordinates	18178
@NP	6.1 mm posterior	18195
@NP	Bregma , 0.7 mm lateral -LRB- right -RRB- of midline	18215
@NP	Bregma	18215
@NP	0.7 mm lateral -LRB- right -RRB- of midline	18223
@NP	0.7 mm lateral -LRB- right -RRB-	18223
@NP	0.7 mm lateral	18223
@NP	right	18239
@NP	midline	18249
@NP	7 mm	18262
@NP	the dura	18277
@NP	The pipette	18287
@NP	place for 10 min	18311
@NP	place	18311
@NP	10 min	18321
@NP	injection	18334
@NP	BDA	18359
@NP	the syringe	18386
@NP	Immunohistochemistry .	18399
@NP	Six weeks	18421
@NP	injury and treatment	18437
@NP	rats	18459
@NP	a lethal dose of chloral hydrate	18487
@NP	a lethal dose	18487
@NP	chloral hydrate	18504
@NP	100 mg/kg , i.p. ; BDH Chemicals , Toronto , Ontario , Canada	18521
@NP	100 mg/kg , i.p. ; BDH Chemicals , Toronto , Ontario ,	18521
@NP	100 mg/kg , i.p.	18521
@NP	100 mg/kg	18521
@NP	BDH Chemicals , Toronto , Ontario ,	18538
@NP	BDH Chemicals	18538
@NP	Toronto , Ontario ,	18553
@NP	Canada	18571
@NP	PBS	18612
@NP	phosphate	18629
@NP	4 %	18648
@NP	paraformaldehyde -LRB- pH 7.4 -RRB-	18651
@NP	paraformaldehyde	18651
@NP	pH 7.4	18669
@NP	The midbrain , the cerebellum , and the cervical spinal cords	18678
@NP	The midbrain	18678
@NP	the cerebellum	18692
@NP	the cervical spinal cords	18712
@NP	4 % paraformaldehyde	18767
@NP	24 % sucrose in 0.1 M phosphate buffer over 2 -- 3 days	18815
@NP	24 % sucrose in 0.1 M phosphate buffer over 2	18815
@NP	24 % sucrose	18815
@NP	0.1 M phosphate buffer over 2	18830
@NP	0.1 M phosphate buffer	18830
@NP	2	18858
@NP	3 days	18860
@NP	isopentane over dry ice	18882
@NP	isopentane	18882
@NP	dry ice	18898
@NP	Spinal cord	18907
@NP	20-µm sections on a cryostat	18933
@NP	20-µm sections	18933
@NP	a cryostat	18951
@NP	2808C	18976
@NP	Cervical segments C2 and C7	18983
@NP	Cervical segments C2	18983
@NP	C7	19008
@NP	20-µm sections in the coronal plane	19025
@NP	20-µm sections	19025
@NP	the coronal plane	19043
@NP	Cervical segments from C3 to C6	19062
@NP	Cervical segments	19062
@NP	C3 to C6	19085
@NP	C3	19085
@NP	C6	19091
@NP	20-µm longitudinal sections in the horizontal plane	19108
@NP	20-µm longitudinal sections	19108
@NP	the horizontal plane	19139
@NP	frozen sections	19176
@NP	a slide warmer for 30 min	19207
@NP	a slide warmer	19207
@NP	30 min	19226
@NP	PBS 10 mM	19248
@NP	three times	19258
@NP	5 min each	19274
@NP	5 min	19274
@NP	each	19280
@NP	10 % normal donkey serum -LRB- in 0.1 % Triton X-100 -RRB-	19305
@NP	10 % normal donkey serum	19305
@NP	10 %	19305
@NP	in 0.1 % Triton X-100	19330
@NP	0.1 %	19333
@NP	Triton X-100	19338
@NP	Triton	19338
@NP	X-100	19345
@NP	30 min	19356
@NP	nonspecific binding	19374
@NP	The following primary antibodies	19395
@NP	chicken antigreen	19439
@NP	fluorescent protein -LRB- anti-GFP , 1:1,000 ; Chemicon , Termecula , CA -RRB-	19457
@NP	fluorescent protein	19457
@NP	anti-GFP , 1:1,000 ; Chemicon , Termecula , CA	19478
@NP	anti-GFP	19478
@NP	1:1,000 ; Chemicon	19488
@NP	1:1,000	19488
@NP	Chemicon	19497
@NP	Termecula , CA	19507
@NP	rabbit anti-GFP -LRB- anti-GFP , 1:1,000 ; Chemicon -RRB-	19523
@NP	rabbit anti-GFP	19523
@NP	anti-GFP , 1:1,000 ; Chemicon	19540
@NP	anti-GFP	19540
@NP	1:1,000 ; Chemicon	19550
@NP	1:1,000	19550
@NP	Chemicon	19559
@NP	mouse anti-GFAP -LRB- anti-GFAP , 1:400 ; Sigma -RRB-	19570
@NP	mouse anti-GFAP	19570
@NP	anti-GFAP , 1:400 ; Sigma	19587
@NP	anti-GFAP	19587
@NP	1:400 ; Sigma	19598
@NP	1:400	19598
@NP	Sigma	19605
@NP	mouse antineurofilament 200 -LRB- anti-NF , 1:400 ; Sigma -RRB-	19613
@NP	mouse antineurofilament	19613
@NP	200 -LRB- anti-NF , 1:400 ; Sigma -RRB-	19637
@NP	200	19637
@NP	anti-NF , 1:400 ; Sigma	19642
@NP	anti-NF	19642
@NP	1:400 ; Sigma	19651
@NP	1:400	19651
@NP	Sigma	19658
@NP	mouse anti-bIIItubulin	19666
@NP	anti-tub , 1:400 ; Sigma	19690
@NP	anti-tub	19690
@NP	1:400 ; Sigma	19700
@NP	1:400	19700
@NP	Sigma	19707
@NP	mouse anti-Ki67	19719
@NP	BD Biosciences	19736
@NP	Mississauga	19752
@NP	Ontario , Canada	19765
@NP	All primary antibodies	19783
@NP	24 hr at room temperature	19823
@NP	24 hr	19823
@NP	room temperature	19832
@NP	Secondary antibodies -LRB- 1:200 ; Jackson Immunoresearch -RRB-	19850
@NP	Secondary antibodies	19850
@NP	1:200 ; Jackson Immunoresearch	19872
@NP	1:200	19872
@NP	Jackson Immunoresearch	19879
@NP	donkey	19913
@NP	Alexa 350 , Alexa 488 , and Cy3	19935
@NP	Alexa 350	19935
@NP	Alexa 488	19946
@NP	Cy3	19961
@NP	2	19986
@NP	3 hr at room temperature	19988
@NP	3 hr	19988
@NP	room temperature	19996
@NP	BDA	20014
@NP	Cy3	20042
@NP	AMCA-conjugated streptavidin	20050
@NP	1:400 ; Jackson Immunoresearch	20080
@NP	1:400	20080
@NP	Jackson Immunoresearch	20087
@NP	West Grove , PA	20111
@NP	West Grove	20111
@NP	PA	20123
@NP	2	20139
@NP	3 hr at room temperature	20141
@NP	3 hr	20141
@NP	room temperature	20149
@NP	Sections	20167
@NP	glycerol mounting liquid -LRB- Sigma -RRB-	20197
@NP	glycerol mounting liquid	20197
@NP	Sigma	20223
@NP	In situ hybridization .	20231
@NP	In situ	20231
@NP	hybridization	20239
@NP	The protocol given by Verge et al. -LRB- 1992 -RRB-	20254
@NP	The protocol	20254
@NP	Verge	20276
@NP	et al.	20282
@NP	1992	20290
@NP	some modification	20311
@NP	The Ta1	20330
@NP	tubulin probe	20339
@NP	a 50-oligomer oligonucleotide	20357
@NP	the 30-untranslated sequence	20404
@NP	Ta1-tubulin 5AAACCCATCAGTGAAGTGGACGGCTCGGGTCTCTG ACAAATCATT CA-3	20436
@NP	the GAP-43 probe	20506
@NP	bases 220 -- 270 -LRB- Basi et al. , 1987 -RRB-	20544
@NP	bases 220 -- 270	20544
@NP	bases	20544
@NP	220 -- 270	20550
@NP	Basi	20559
@NP	et al. , 1987	20564
@NP	et al.	20564
@NP	1987	20572
@NP	These oligonucleotide probes	20579
@NP	35S-ATP	20630
@NP	deoxynucleotide terminal transferase	20644
@NP	a standard protocol	20694
@NP	GAP-43 and Ta1-tubulin ISH	20719
@NP	four sections from each animal	20747
@NP	four sections	20747
@NP	each animal	20766
@NP	that	20788
@NP	106 cpm of probe	20831
@NP	106 cpm	20831
@NP	probe	20842
@NP	16	20852
@NP	18 hr at 43 °C -LRB- for details see Giehl and Tetzlaff , 1996 -RRB-	20855
@NP	18 hr	20855
@NP	43 °C -LRB- for details see Giehl and Tetzlaff , 1996 -RRB-	20864
@NP	43 °C	20864
@NP	details	20874
@NP	Giehl and Tetzlaff , 1996	20886
@NP	Giehl and Tetzlaff	20886
@NP	1996	20906
@NP	The slides	20913
@NP	Kodak NTB-2 emulsion	20939
@NP	3 days for Ta1-tubulin and 7 days for GAP-43	20981
@NP	3 days for Ta1-tubulin	20981
@NP	3 days	20981
@NP	Ta1-tubulin	20992
@NP	7 days for GAP-43	21008
@NP	7 days	21008
@NP	GAP-43	21019
@NP	We	21027
@NP	GAP-43 and Ta1-tubulin probes	21045
@NP	GAP-43	21045
@NP	Ta1-tubulin probes	21056
@NP	a single band of the expected size in Northern blots of RNA	21080
@NP	a single band	21080
@NP	the expected size in Northern blots of RNA	21097
@NP	the expected size	21097
@NP	Northern blots of RNA	21118
@NP	Northern blots	21118
@NP	RNA	21136
@NP	facial nuclei	21145
@NP	identical or less stringent hybridization conditions	21165
@NP	Tetzlaff	21219
@NP	et al. , 1991	21228
@NP	et al.	21228
@NP	1991	21236
@NP	Sense-control probes	21243
@NP	no specific binding -LRB- data not shown -RRB-	21271
@NP	no specific binding	21271
@NP	data not shown	21292
@NP	data	21292
@NP	We	21309
@NP	essentially the same results	21321
@NP	GAP-43 and Ta1-tubulin ISH in no-pump control animals and our previous study	21354
@NP	GAP-43 and Ta1-tubulin ISH	21354
@NP	no-pump control animals and our previous study	21384
@NP	no-pump control animals	21384
@NP	our previous study	21412
@NP	cDNA probes of several hundred base pairs -LRB- Tetzlaff et al. , 1991 -RRB-	21437
@NP	cDNA probes	21437
@NP	several hundred base pairs -LRB- Tetzlaff et al. , 1991 -RRB-	21452
@NP	several hundred base pairs	21452
@NP	Tetzlaff	21480
@NP	et al. , 1991	21489
@NP	et al.	21489
@NP	1991	21497
@NP	the oligonucleotide probes in this study	21516
@NP	the oligonucleotide probes	21516
@NP	this study	21546
@NP	the low levels of GAP-43 and Ta1-tubulin	21566
@NP	the low levels	21566
@NP	GAP-43 and Ta1-tubulin	21584
@NP	the contralateral control rubrospinal neurons	21610
@NP	their higher sensitivity	21667
@NP	Image Analysis and Quantification Slides	21693
@NP	blind the observer	21748
@NP	images	21772
@NP	an Axioplan 2 microscope -LRB- Zeiss , Jena , Germany -RRB-	21808
@NP	an Axioplan 2 microscope	21808
@NP	Zeiss	21834
@NP	Jena	21841
@NP	Germany	21847
@NP	a digital camera -LRB- QImaging , Burnaby , British Columbia , Canada -RRB-	21857
@NP	a digital camera	21857
@NP	QImaging , Burnaby , British Columbia , Canada	21875
@NP	QImaging	21875
@NP	Burnaby	21885
@NP	British Columbia	21894
@NP	Canada	21912
@NP	Northern Eclipse software	21925
@NP	Empix Imaging	21952
@NP	Inc. , Mississauga	21967
@NP	Ontario , Canada	21986
@NP	Digital images	22004
@NP	Photoshop 7.0 -LRB- Adobe Systems , San Jose , CA -RRB-	22042
@NP	Photoshop 7.0	22042
@NP	Adobe Systems	22057
@NP	San Jose	22072
@NP	CA	22082
@NP	SigmaScan Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	22087
@NP	SigmaScan	22087
@NP	Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	22097
@NP	Pro	22097
@NP	SPSS Inc.	22102
@NP	Chicago	22113
@NP	IL	22122
@NP	Matlab 6.5 -LRB- The MathWorks , Inc. , Natick , MA -RRB- software	22131
@NP	Matlab 6.5 -LRB- The MathWorks , Inc. , Natick , MA -RRB-	22131
@NP	Matlab 6.5	22131
@NP	The MathWorks	22143
@NP	Inc.	22158
@NP	Natick , MA	22164
@NP	GFAP immunoreactivity	22186
@NP	the density	22235
@NP	a 50-µm-wide area	22254
@NP	the rim of the lesion site on three longitudinal sections	22278
@NP	the rim	22278
@NP	the lesion site on three longitudinal sections	22289
@NP	the lesion site	22289
@NP	three longitudinal sections	22308
@NP	animal	22341
@NP	the horizontal plane	22360
@NP	the dorsal root entry zone and the central canal	22409
@NP	the dorsal root entry zone	22409
@NP	the central canal	22440
@NP	This density value	22459
@NP	the value	22496
@NP	an analogous area on the contralateral uninjured side of the spinal cord	22520
@NP	an analogous area	22520
@NP	the contralateral uninjured side of the spinal cord	22541
@NP	the contralateral uninjured side	22541
@NP	the spinal cord	22577
@NP	Immunopositive cellular or axonal density measurements	22594
@NP	axonal density	22621
@NP	Ramer	22667
@NP	et al. -LRB- 2004b ;	22673
@NP	et al.	22673
@NP	2004b	22681
@NP	Fig. 2A	22692
@NP	Lesion area and cavity size	22702
@NP	Lesion area	22702
@NP	cavity size	22718
@NP	each animal	22750
@NP	the lesion area	22775
@NP	GFAP immunoreactivity	22802
@NP	three	22827
@NP	levels	22841
@NP	the dorsal root entry zone and the central canal	22876
@NP	the dorsal root entry zone	22876
@NP	the central canal	22907
@NP	the total pixels in this area -LRB- Fig. 2B -- D -RRB-	22941
@NP	the total pixels	22941
@NP	this area -LRB- Fig. 2B -- D -RRB-	22961
@NP	this area	22961
@NP	Fig. 2B -- D	22972
@NP	Fig. 2B	22972
@NP	D	22980
@NP	Measurements of OECs	22984
@NP	Measurements	22984
@NP	OECs	23000
@NP	Fig. 3	23026
@NP	Fig. 4 -RRB- through OEC transplants	23060
@NP	Fig.	23060
@NP	4 -RRB- through OEC transplants	23065
@NP	through	23068
@NP	transplants	23080
@NP	elsewhere -LRB- Ramer et al.	23120
@NP	elsewhere	23120
@NP	Ramer et al.	23131
@NP	Ramer	23131
@NP	et al.	23137
@NP	2001 , 2004b ; MacDermid et al.	23145
@NP	2001 , 2004b	23145
@NP	2001	23145
@NP	2004b	23151
@NP	et al.	23168
@NP	2004 ; Scott et al. , 2005	23176
@NP	2004	23176
@NP	Scott et al. , 2005	23182
@NP	Scott	23182
@NP	et al. , 2005	23188
@NP	et al.	23188
@NP	2005	23196
@NP	Bretzner et al. , 2008	23202
@NP	Bretzner	23202
@NP	et al. , 2008	23211
@NP	et al.	23211
@NP	2008	23219
@NP	The method	23226
@NP	Information Figure 7	23286
@NP	brief	23311
@NP	a Laplace	23318
@NP	the edges of the immunoreactive cellular or axonal profiles	23364
@NP	the edges	23364
@NP	the immunoreactive cellular or axonal profiles	23377
@NP	Info .	23431
@NP	7B	23442
@NP	This	23447
@NP	works	23462
@NP	an edge-detection filter	23471
@NP	all immunopositive processes	23509
@NP	their relative intensity	23552
@NP	These images	23578
@NP	overlays in which all pixels overlying immunopositive profiles had a value of 68	23625
@NP	overlays	23625
@NP	all pixels overlying immunopositive profiles	23643
@NP	all pixels	23643
@NP	immunopositive profiles	23664
@NP	a value of 68	23692
@NP	a value	23692
@NP	68	23703
@NP	all other pixels	23711
@NP	a value of 0	23732
@NP	a value	23732
@NP	0	23743
@NP	the resulting pixel values	23758
@NP	68	23788
@NP	a binary map of the image	23792
@NP	a binary map	23792
@NP	the image	23808
@NP	number of pixels	23837
@NP	number	23837
@NP	pixels	23847
@NP	function of the window area	23884
@NP	function	23884
@NP	the window area	23896
@NP	average intensity	23919
@NP	this manner	23944
@NP	density measurements -LRB- for examples	23969
@NP	density measurements	23969
@NP	examples	23995
@NP	Supp	24008
@NP	Info .	24014
@NP	Figs. 7C , 8 -RRB-	24020
@NP	Figs.	24020
@NP	7C , 8 -RRB-	24026
@NP	7C	24026
@NP	Three measurement windows	24034
@NP	the lesion epicenter	24083
@NP	either the rostral or the caudal edges	24107
@NP	the rostral	24114
@NP	the caudal edges	24129
@NP	the graft in order	24149
@NP	the graft	24149
@NP	order	24162
@NP	the number of pixels along this axis -LRB- Supp	24179
@NP	the number	24179
@NP	pixels along this axis -LRB- Supp	24193
@NP	pixels	24193
@NP	Supp	24217
@NP	Info .	24223
@NP	Fig.	24229
@NP	Cell profile density measurements	24239
@NP	these three measurement windows	24305
@NP	each side of the lesion , i.e. , rostral and caudal	24342
@NP	each side	24342
@NP	the lesion , i.e. , rostral and caudal	24355
@NP	the lesion	24355
@NP	i.e.	24367
@NP	rostral	24373
@NP	caudal	24385
@NP	three sections per animal	24413
@NP	three sections	24413
@NP	animal	24432
@NP	each treatment group	24459
@NP	a function	24507
@NP	the distance	24521
@NP	the lesion epicenter	24539
@NP	Info .	24567
@NP	Fig.	24573
@NP	The same procedure	24583
@NP	a measure	24624
@NP	OECs transplants -LRB- see Fig. 4 -RRB-	24666
@NP	OECs transplants	24666
@NP	Fig. 4	24688
@NP	the gray matter rostral	24729
@NP	the lesion	24756
@NP	Fig. 5C	24773
@NP	Cell density	24783
@NP	cell profile density in the rest of this paper	24819
@NP	cell profile density	24819
@NP	the rest of this paper	24843
@NP	the rest	24843
@NP	this paper	24855
@NP	we	24871
@NP	any changes in numbers	24890
@NP	any changes	24890
@NP	numbers	24905
@NP	changes in cell size	24918
@NP	changes	24918
@NP	cell size	24929
@NP	Rubrospinal regeneration	24940
@NP	the presence	24995
@NP	traced axons	25011
@NP	the spinal cord	25035
@NP	every other 20-µm section	25054
@NP	the longitudinal -LRB- horizontal -RRB- plane	25089
@NP	we	25153
@NP	any evidence for axonal regeneration	25169
@NP	any evidence	25169
@NP	axonal regeneration	25186
@NP	we	25207
@NP	each animal	25234
@NP	the distances	25246
@NP	the terminal ends	25268
@NP	the most caudal five rubrospinal axon tips and the lesion epicenter	25289
@NP	five rubrospinal axon tips and the lesion epicenter	25305
@NP	five rubrospinal axon tips	25305
@NP	the lesion epicenter	25336
@NP	the three best	25363
@NP	longitudinal sections of the rubrospinal tract	25385
@NP	longitudinal sections	25385
@NP	the rubrospinal tract	25410
@NP	the dorsolateral funiculus	25435
@NP	This	25463
@NP	a measure of rubrospinal axon retraction	25479
@NP	a measure	25479
@NP	rubrospinal axon retraction	25492
@NP	Fig. 5A , B	25525
@NP	Fig. 5A	25525
@NP	B	25533
@NP	addition to this	25540
@NP	addition	25540
@NP	this	25552
@NP	we	25558
@NP	the extent of rubrospinal branches/sprouts	25570
@NP	the extent	25570
@NP	rubrospinal branches/sprouts	25584
@NP	the gray matter on three different cervical coronal sections	25620
@NP	the gray matter	25620
@NP	three different cervical coronal sections	25639
@NP	C2	25684
@NP	These values	25688
@NP	the number	25720
@NP	rubrospinal axons	25734
@NP	the dorsolateral funiculus on three different cervical coronal sections	25768
@NP	the dorsolateral funiculus	25768
@NP	three different cervical coronal sections	25798
@NP	C2 -LRB- see Fig. 5C -RRB-	25843
@NP	C2	25843
@NP	Fig. 5C	25851
@NP	Statistical Analysis A two-way repeated ANOVA	25861
@NP	Statistical Analysis A two-way	25861
@NP	Statistical Analysis	25861
@NP	A two-way	25882
@NP	ANOVA	25901
@NP	interactions between treatment and distance	25926
@NP	interactions	25926
@NP	treatment and distance	25947
@NP	the axonal and cellular density	25974
@NP	interactions between treatment and time course	26020
@NP	interactions	26020
@NP	treatment and time course	26041
@NP	the behavioral outcomes	26071
@NP	A one-way ANOVA	26096
@NP	differences in the axonal or cellular density	26131
@NP	differences	26131
@NP	the axonal or cellular density	26146
@NP	each given distance	26180
@NP	differences in behavioral outcome measurements	26214
@NP	differences	26214
@NP	behavioral outcome measurements	26229
@NP	each time point	26264
@NP	A oneway ANOVA	26281
@NP	differences	26315
@NP	density measurements	26344
@NP	rubrospinal axon retraction and lesion area measurements	26376
@NP	the treatment	26446
@NP	The data	26461
@NP	further analyzed using the post hoc Tukey - Kramer test	26475
@NP	further	26475
@NP	the post hoc Tukey	26498
@NP	the post	26498
@NP	Kramer test	26518
@NP	the cases in which the variables did not fit a normal distribution	26534
@NP	the cases	26534
@NP	the variables	26553
@NP	a normal distribution	26579
@NP	the nonparametric Kruskal-Wallis	26602
@NP	sum test	26642
@NP	a x2 test	26673
@NP	all cases	26687
@NP	P values	26698
@NP	0.05 -LRB- two-tailed -RRB-	26708
@NP	0.05	26708
@NP	RESULTS	26756
@NP	I.	26770
@NP	Experimental Design	26773
@NP	* Different combinatorial therapies and the number of animal used	26795
@NP	* Different combinatorial therapies and the number	26795
@NP	Different combinatorial therapies and the	26796
@NP	Different combinatorial therapies	26796
@NP	the	26834
@NP	number	26838
@NP	animal used	26848
@NP	animal	26848
@NP	histological and behavioral quantifications	26864
@NP	Histology	26909
@NP	Number	26920
@NP	the total number of animals used for histology	26937
@NP	the total number	26937
@NP	animals used for histology	26957
@NP	animals	26957
@NP	histology	26974
@NP	Numbers in parentheses	26985
@NP	Numbers	26985
@NP	parentheses	26996
@NP	the number	27012
@NP	animals	27026
@NP	BDA	27059
@NP	the dieback	27084
@NP	rubrospinal axons	27113
@NP	Fig. 1 .	27133
@NP	Fig.	27133
@NP	1	27138
@NP	Cell body treatment of the red nucleus infusing cAMP and OEC transplants	27141
@NP	Cell body treatment	27141
@NP	the red nucleus infusing cAMP and OEC transplants	27164
@NP	the red nucleus	27164
@NP	cAMP and OEC transplants	27189
@NP	regeneration of rubrospinal axons	27231
@NP	regeneration	27231
@NP	rubrospinal axons	27247
@NP	Rubrospinal axons -LRB- BDA in red -RRB- , LP-OECs -LRB- GFP in green -RRB-	27266
@NP	Rubrospinal axons	27266
@NP	BDA in red	27285
@NP	BDA	27285
@NP	red	27292
@NP	LP-OECs -LRB- GFP in green -RRB-	27298
@NP	LP-OECs	27298
@NP	GFP in green	27307
@NP	GFP	27307
@NP	glial scar -LRB- GFAP in blue -RRB- in typical longitudinal sections	27326
@NP	glial scar -LRB- GFAP in blue -RRB-	27326
@NP	glial scar	27326
@NP	GFAP in blue	27338
@NP	GFAP	27338
@NP	blue	27346
@NP	typical longitudinal sections	27355
@NP	the horizontal plane of spinal cords	27388
@NP	the horizontal plane	27388
@NP	spinal cords	27412
@NP	a vehicle-DMEM-treated rat	27430
@NP	A	27458
@NP	vehicle	27475
@NP	the rubrospinal neuron level and DMEM	27486
@NP	the rubrospinal neuron level	27486
@NP	DMEM	27519
@NP	the spinal cord level	27527
@NP	cAMP-DMEM-treated rat -LRB- B -RRB-	27550
@NP	cAMP-DMEM-treated rat	27550
@NP	B	27573
@NP	vehicle-OECs-treated rat -LRB- C -RRB-	27577
@NP	vehicle-OECs-treated rat	27577
@NP	C	27603
@NP	cAMP-OECs-treated rat -LRB- D -RRB-	27611
@NP	cAMP-OECs-treated rat	27611
@NP	D	27634
@NP	the lesion epicenter 310	27649
@NP	Scale	27675
@NP	5 250 µm	27685
@NP	-LSB- Color figure	27695
@NP	the online issue , which is available at wileyonlinelibrary.com	27726
@NP	the online issue	27726
@NP	wileyonlinelibrary.com	27766
@NP	Fig. 2 .	27792
@NP	Fig.	27792
@NP	2	27797
@NP	OECs	27800
@NP	the lesion	27810
@NP	cavity and glial scar formation	27832
@NP	A : GFAP immunodensity along the lesion site	27865
@NP	GFAP immunodensity along the lesion	27868
@NP	GFAP immunodensity	27868
@NP	the lesion	27893
@NP	the contralateral noninjured side	27923
@NP	B : Mean lesion area -LRB- GFAP negative area -RRB- .	27958
@NP	B	27958
@NP	Mean lesion area -LRB- GFAP negative area -RRB-	27961
@NP	Mean lesion area	27961
@NP	GFAP negative area	27979
@NP	C : Mean cavity formation area -LRB- area within the lesion site -RRB- .	28000
@NP	C	28000
@NP	Mean cavity formation area -LRB- area within the lesion site -RRB-	28003
@NP	Mean cavity formation area	28003
@NP	area within the lesion site	28031
@NP	area	28031
@NP	the lesion site	28043
@NP	D : Percentage of lesion site occupied by cavity .	28061
@NP	D	28061
@NP	Percentage of lesion site occupied by cavity	28064
@NP	Percentage	28064
@NP	lesion site	28078
@NP	cavity	28102
@NP	Error bars	28110
@NP	SEM	28130
@NP	one-way ANOVA	28135
@NP	Tukey-Kramer test for B	28161
@NP	Tukey-Kramer test	28161
@NP	B	28183
@NP	Kruskal-Wallis	28190
@NP	v2 test for A , C , D , * P < 0.05 compared with vehicle-DMEM	28217
@NP	v2 test for A , C , D , * P < 0.05	28217
@NP	v2 test	28217
@NP	A , C , D ,	28229
@NP	P <	28237
@NP	P	28237
@NP	<	28239
@NP	0.05	28241
@NP	vehicle-DMEM	28260
@NP	@P < 0.05 compared with vehicle	28274
@NP	@P	28274
@NP	vehicle	28298
@NP	DMEM and cAMP-DMEM	28307
@NP	DMEM	28307
@NP	cAMP-DMEM	28316
@NP	P < 0.05 compared with vehicle - DMEM and DMEM-rolipram	28328
@NP	P < 0.05 compared with vehicle	28328
@NP	P	28328
@NP	vehicle	28351
@NP	DMEM and DMEM-rolipram	28360
@NP	DMEM	28360
@NP	DMEM-rolipram	28369
@NP	Veh , vehicle ; Rolip , rolipram .	28385
@NP	Veh , vehicle	28385
@NP	Veh	28385
@NP	vehicle	28390
@NP	Rolip , rolipram	28399
@NP	Rolip	28399
@NP	rolipram	28406
@NP	Fig. 3 .	28417
@NP	Fig.	28417
@NP	3	28422
@NP	Systemic treatment with rolipram	28425
@NP	Systemic treatment	28425
@NP	rolipram	28449
@NP	the OEC density	28467
@NP	B : High-magnification images	28486
@NP	B	28486
@NP	High-magnification images	28489
@NP	typical longitudinal sections	28520
@NP	the horizontal plane of spinal cords	28553
@NP	the horizontal plane	28553
@NP	spinal cords	28577
@NP	vehicle-OEC-treated rats -LRB- A -RRB- and cAMP-OEC-treated rats -LRB- B -RRB-	28595
@NP	vehicle-OEC-treated rats	28595
@NP	A	28621
@NP	cAMP-OEC-treated rats	28628
@NP	B	28651
@NP	the Schwann cell-like morphology	28660
@NP	C	28694
@NP	OECs density throughout the graft in rats which received cell body treatment	28697
@NP	OECs density	28697
@NP	the graft in rats which received cell body treatment	28721
@NP	the graft	28721
@NP	rats which received cell body treatment	28734
@NP	rats	28734
@NP	cell body treatment	28754
@NP	D : Graft area in rats which received cell body treatment .	28775
@NP	D	28775
@NP	Graft area in rats which received cell body treatment	28778
@NP	Graft area	28778
@NP	rats which received cell body treatment	28792
@NP	rats	28792
@NP	cell body treatment	28812
@NP	E , F	28833
@NP	E	28833
@NP	F	28835
@NP	High-magnification images	28838
@NP	GFP-OECs	28867
@NP	GFP in green	28877
@NP	GFP	28877
@NP	axons	28895
@NP	NF200 and bIII-tubulin in red	28902
@NP	NF200 and bIII-tubulin	28902
@NP	red	28928
@NP	typical longitudinal sections	28938
@NP	the horizontal plane	28971
@NP	spinal cords	28995
@NP	vehicle-OEC-treated rats -LRB- E -RRB- and cAMP-OEC-treated rats -LRB- F -RRB-	29013
@NP	vehicle-OEC-treated rats	29013
@NP	E	29039
@NP	cAMP-OEC-treated rats	29046
@NP	F	29069
@NP	that OECs	29078
@NP	some thin and thick axons regardless of the treatment	29099
@NP	some thin and thick axons	29099
@NP	the treatment	29139
@NP	G	29154
@NP	L : Similar to A -- F in rats that received systemic treatment with rolipram	29156
@NP	L	29156
@NP	Similar to A -- F in rats that received systemic treatment with rolipram	29159
@NP	Similar	29159
@NP	A -- F in rats	29170
@NP	F in rats	29172
@NP	F	29172
@NP	rats	29177
@NP	systemic treatment	29196
@NP	rolipram	29220
@NP	One-way ANOVA	29230
@NP	Tukey-Kramer test or Kruskal-Wallis followed by x2 test	29256
@NP	Tukey-Kramer test or Kruskal-Wallis	29256
@NP	x2 test	29304
@NP	* P < 0.05 OEC-rolipram compared with OEC	29313
@NP	* P < 0.05 OEC-rolipram	29313
@NP	P <	29314
@NP	P	29314
@NP	<	29316
@NP	0.05 OEC-rolipram	29318
@NP	OEC	29350
@NP	Scale bars	29355
@NP	50 µm	29368
@NP	-LSB- Color figure	29375
@NP	the online issue , which is available at wileyonlinelibrary.com	29406
@NP	the online issue	29406
@NP	wileyonlinelibrary.com	29446
@NP	Fig. 4 .	29472
@NP	Fig.	29472
@NP	4	29477
@NP	Systemic treatment with rolipram	29480
@NP	Systemic treatment	29480
@NP	rolipram	29504
@NP	axonal density	29522
@NP	OEC transplants	29545
@NP	Typical longitudinal sections	29562
@NP	the horizontal plane of spinal cords	29595
@NP	the horizontal plane	29595
@NP	spinal cords	29619
@NP	vehicle-OEC-treated rats -LRB- A -RRB- and cAMP-OEC-treated rats -LRB- B -RRB-	29637
@NP	vehicle-OEC-treated rats	29637
@NP	A	29663
@NP	cAMP-OEC-treated rats	29670
@NP	B	29693
@NP	C	29697
@NP	Density	29700
@NP	thin and thick axons -LRB- NF200 - and bIII-tubulinpositive structures -RRB-	29711
@NP	thin and thick axons	29711
@NP	NF200	29733
@NP	bIII-tubulinpositive structures	29744
@NP	rats that received cell body treatment	29780
@NP	rats	29780
@NP	cell body treatment	29799
@NP	D	29820
@NP	F : Similar to A -- C in rats that received systemic treatment with rolipram	29822
@NP	F	29822
@NP	Similar to A -- C in rats that received systemic treatment with rolipram	29825
@NP	Similar	29825
@NP	A -- C in rats	29836
@NP	C in rats	29838
@NP	C	29838
@NP	rats	29843
@NP	systemic treatment	29862
@NP	rolipram	29886
@NP	One-way ANOVA	29896
@NP	Tukey-Kramer test or Kruskal-Wallis followed by v2 test	29922
@NP	Tukey-Kramer test or Kruskal-Wallis	29922
@NP	v2 test	29970
@NP	* P < 0.05 OEC-rolipram compared with OEC	29979
@NP	* P < 0.05 OEC-rolipram	29979
@NP	P <	29980
@NP	P	29980
@NP	<	29982
@NP	0.05 OEC-rolipram	29984
@NP	OEC	30016
@NP	Fig. 5 .	30022
@NP	Fig.	30022
@NP	5	30027
@NP	OEC transplants and cAMP elevation	30030
@NP	OEC transplants	30030
@NP	cAMP elevation	30050
@NP	regeneration	30081
@NP	retraction of rubrospinal tract axons	30106
@NP	retraction	30106
@NP	rubrospinal tract axons	30120
@NP	lesion epicenter	30149
@NP	A : Distance of rubrospinal axonal terminals from the lesion epicenter	30167
@NP	Distance of rubrospinal axonal terminals from the lesion epicenter	30170
@NP	Distance	30170
@NP	rubrospinal axonal terminals from the lesion epicenter	30182
@NP	rubrospinal axonal terminals	30182
@NP	the lesion epicenter	30216
@NP	a function of different treatments	30240
@NP	a function	30240
@NP	different treatments	30254
@NP	B	30276
@NP	Distance of rubrospinal axonal terminals from the lesion epicenter	30279
@NP	Distance	30279
@NP	rubrospinal axonal terminals from the lesion epicenter	30291
@NP	rubrospinal axonal terminals	30291
@NP	the lesion epicenter	30325
@NP	the number	30360
@NP	rubrospinal axons	30374
@NP	the dorsolateral funiculus at the cervical segment C2 rostral	30407
@NP	the dorsolateral funiculus	30407
@NP	the cervical segment C2 rostral	30437
@NP	the lesion	30472
@NP	C	30484
@NP	rubrospinal axon profile index at the cervical segment C2 rostral	30498
@NP	rubrospinal axon profile index	30498
@NP	the cervical segment C2 rostral	30532
@NP	the lesion site	30567
@NP	Error bars	30584
@NP	SEM	30604
@NP	one-way ANOVA	30609
@NP	Tukey-Kramer test for B	30635
@NP	Tukey-Kramer test	30635
@NP	B	30657
@NP	Kruskal-Wallis	30664
@NP	v2 test for A , C , * P < 0.05 compared with the control group vehicle - DMEM	30691
@NP	v2 test for A , C , * P < 0.05	30691
@NP	v2 test	30691
@NP	A , C ,	30703
@NP	C	30705
@NP	P <	30709
@NP	P	30709
@NP	<	30711
@NP	0.05	30713
@NP	the control group vehicle - DMEM	30732
@NP	Fig. 6 .	30767
@NP	Fig.	30767
@NP	6	30772
@NP	Thermal hypersensitivity resulting from OEC transplants .	30775
@NP	Thermal hypersensitivity	30775
@NP	OEC transplants	30815
@NP	Time courses	30832
@NP	the latency	30848
@NP	withdrawal reflexes	30863
@NP	thermal stimulation before and after spinal cord injury	30886
@NP	thermal stimulation	30886
@NP	spinal cord injury	30923
@NP	treatments in the left forepaw -LRB- top panels -RRB-	30946
@NP	treatments	30946
@NP	the left forepaw -LRB- top panels -RRB-	30960
@NP	the left forepaw	30960
@NP	top panels	30978
@NP	the right forepaw -LRB- bottom panels -RRB-	30997
@NP	the right forepaw	30997
@NP	bottom panels	31016
@NP	rats	31034
@NP	the cell body treatment -LRB- A , B -RRB- or the systemic treatment	31054
@NP	the cell body treatment	31054
@NP	A , B	31079
@NP	A	31079
@NP	B	31081
@NP	the systemic treatment	31087
@NP	Kruskal-Wallis	31117
@NP	x2 test	31144
@NP	P	31154
@NP	0.05 veh-OEC or OEC compared with veh-DMEM , + P <	31158
@NP	0.05 veh-OEC	31158
@NP	OEC compared with veh-DMEM , + P <	31174
@NP	OEC	31174
@NP	veh-DMEM , + P <	31192
@NP	veh-DMEM	31192
@NP	P <	31203
@NP	P	31203
@NP	0.05 OECrolipram compared with veh-DMEM , #dbcAMP compared with veh-DMEM , /	31207
@NP	0.05 OECrolipram	31207
@NP	veh-DMEM	31238
@NP	#dbcAMP	31248
@NP	veh-DMEM	31270
@NP	P <	31282
@NP	P	31282
@NP	0.05 OEC	31286
@NP	rolipram and OECrolipram	31309
@NP	Fig. 7 .	31336
@NP	Fig.	31336
@NP	7	31341
@NP	Systemic treatment infusing rolipram in combination with OEC transplants	31344
@NP	Systemic treatment infusing rolipram	31344
@NP	combination with OEC transplants	31384
@NP	combination	31384
@NP	OEC transplants	31401
@NP	the functional recovery of the left injured forelimb	31426
@NP	the functional recovery	31426
@NP	the left injured forelimb	31453
@NP	Time courses	31480
@NP	functional usage	31496
@NP	the left injured forelimb	31516
@NP	injury and treatments	31559
@NP	the cylinder test	31585
@NP	top panels	31604
@NP	the food-pellet-reaching task	31620
@NP	bottom panels	31651
@NP	rats	31669
@NP	the cell body treatment -LRB- A , B -RRB-	31688
@NP	the cell body treatment	31688
@NP	A , B	31713
@NP	A	31713
@NP	B	31715
@NP	the systemic treatment -LRB- C , D -RRB-	31721
@NP	the systemic treatment	31721
@NP	Kruskal-Wallis	31751
@NP	x2 test	31778
@NP	P	31788
@NP	0.05 OEC-rolipram compared with veh-DMEM	31792
@NP	0.05 OEC-rolipram	31792
@NP	veh-DMEM	31824
@NP	We	31835
@NP	rubrospinal axons	31865
@NP	transplants	31899
@NP	OECs	31914
@NP	the lamina propria -LRB- LP-OEC -RRB-	31932
@NP	the lamina propria	31932
@NP	LP-OEC	31952
@NP	the site	31980
@NP	a cervical dorsolateral funiculus crush -LRB- Ramer et al. , 2004a -RRB-	31992
@NP	a cervical dorsolateral funiculus crush	31992
@NP	Ramer	32033
@NP	et al. , 2004a	32039
@NP	et al.	32039
@NP	2004a	32047
@NP	there	32064
@NP	no evidence for regeneration of rubrospinal axons	32074
@NP	no evidence	32074
@NP	regeneration of rubrospinal axons	32090
@NP	regeneration	32090
@NP	rubrospinal axons	32106
@NP	the lesion site -LRB- Ramer et al. , 2004a -RRB-	32131
@NP	the lesion site	32131
@NP	Ramer	32148
@NP	et al. , 2004a	32154
@NP	et al.	32154
@NP	2004a	32162
@NP	the present study	32173
@NP	we	32192
@NP	the OECs	32208
@NP	we	32249
@NP	earlier studies	32265
@NP	this further reduced cavity formation	32286
@NP	glial scar formation at the lesion boundary	32328
@NP	glial scar formation	32328
@NP	the lesion boundary	32352
@NP	enhanced growth of neurofilament positive axons	32376
@NP	enhanced growth	32376
@NP	neurofilament positive axons	32395
@NP	the lesion site in comparison	32429
@NP	the lesion site	32429
@NP	comparison	32448
@NP	a direct transplantation	32464
@NP	the lesion -LRB- Richter et al. , 2005 -RRB-	32494
@NP	the lesion	32494
@NP	Richter	32506
@NP	et al. , 2005	32514
@NP	et al.	32514
@NP	2005	32522
@NP	the current study	32532
@NP	this improved transplantation strategy	32551
@NP	a 2-week elevation of dbcAMP	32608
@NP	a 2-week elevation	32608
@NP	dbcAMP	32630
@NP	the cell body of rubrospinal neurons via a direct infusion of dbcAMP	32647
@NP	the cell body	32647
@NP	rubrospinal neurons via a direct infusion of dbcAMP	32664
@NP	rubrospinal neurons	32664
@NP	a direct infusion of dbcAMP	32688
@NP	a direct infusion	32688
@NP	dbcAMP	32709
@NP	the systemic level via subcutaneous infusion	32722
@NP	the systemic level	32722
@NP	subcutaneous infusion	32745
@NP	rolipram	32770
@NP	the cAMP-degrading enzyme phosphodiesterase -LRB- isoform IV ;	32793
@NP	the cAMP-degrading enzyme phosphodiesterase	32793
@NP	isoform IV	32838
@NP	isoform	32838
@NP	IV	32846
@NP	experimental design	32854
@NP	Supp	32878
@NP	Info .	32884
@NP	Fig. 1 and Table I -RRB-	32890
@NP	Fig.	32890
@NP	1 and Table I -RRB-	32895
@NP	1	32895
@NP	Table I	32901
@NP	OECs	32911
@NP	the Lesion	32921
@NP	Cavity and Glial Scar Formation	32940
@NP	Align	32977
@NP	Axons	32988
@NP	We	32994
@NP	cAMP or rolipram	33018
@NP	the behavior of OECs	33043
@NP	the behavior	33043
@NP	OECs	33059
@NP	the injured spinal cord	33067
@NP	Injury of the dorsolateral funiculus in the rat	33092
@NP	Injury	33092
@NP	the dorsolateral funiculus in the rat	33102
@NP	the dorsolateral funiculus	33102
@NP	the rat	33132
@NP	the formation	33159
@NP	a cavity	33176
@NP	a rim of GFAPpositive hypertrophic astrocytes -LRB- Fig. 1A -RRB-	33199
@NP	a rim	33199
@NP	GFAPpositive hypertrophic astrocytes -LRB- Fig. 1A -RRB-	33208
@NP	GFAPpositive hypertrophic astrocytes	33208
@NP	Fig. 1A	33246
@NP	Examples of the treated spinal cords	33256
@NP	Examples	33256
@NP	the treated spinal cords	33268
@NP	Figure 1	33306
@NP	our previous reports -LRB- Ramer et al. , 2004a ; Richter et al. , 2005 -RRB-	33322
@NP	our previous reports	33322
@NP	Ramer	33344
@NP	et al. , 2004a ; Richter et al. , 2005	33350
@NP	et al.	33350
@NP	2004a ; Richter et al.	33358
@NP	2004a	33358
@NP	Richter et al.	33365
@NP	Richter	33365
@NP	et al.	33373
@NP	2005	33381
@NP	we	33388
@NP	three OEC transplant groups -LRB- Veh-OEC ; cAMP-OEC , and rolipram-OEC -RRB-	33402
@NP	three OEC transplant groups	33402
@NP	Veh-OEC ; cAMP-OEC , and rolipram-OEC	33431
@NP	Veh-OEC	33431
@NP	cAMP-OEC , and rolipram-OEC	33440
@NP	cAMP-OEC	33440
@NP	rolipram-OEC	33454
@NP	the GFAP immunoreactivity	33480
@NP	the lesion edge	33513
@NP	a reduced astrocytic activation -LRB- Fig. 2A -RRB-	33543
@NP	a reduced astrocytic activation	33543
@NP	Fig. 2A	33576
@NP	OECs	33586
@NP	the lesion site	33628
@NP	many OECs interdigitating with the host environment	33650
@NP	many OECs	33650
@NP	the host environment	33681
@NP	The demarcation by reactive astrocytes -LRB- GFAPpositive lesion boundary -RRB-	33703
@NP	The demarcation by reactive astrocytes	33703
@NP	The demarcation	33703
@NP	reactive astrocytes	33722
@NP	GFAPpositive lesion boundary	33743
@NP	the lesion area -LRB- defined by a disrupted spinal cord cytoarchitecture -RRB-	33793
@NP	the lesion area	33793
@NP	a disrupted spinal cord cytoarchitecture	33821
@NP	a	33821
@NP	spinal cord cytoarchitecture	33833
@NP	All OEC treatment groups	33864
@NP	combination with cAMP-increasing strategies	33902
@NP	combination	33902
@NP	cAMP-increasing strategies	33919
@NP	the size of the lesion area -LRB- Fig. 2B -RRB-	33966
@NP	the size	33966
@NP	the lesion area -LRB- Fig. 2B -RRB-	33978
@NP	the lesion area	33978
@NP	Fig. 2B	33995
@NP	most of the lesion site	34021
@NP	most	34021
@NP	the lesion site	34029
@NP	they	34046
@NP	only a small fraction	34056
@NP	the lesion occupied by cavity -LRB- Figs. 1C , D , 2C , D -RRB-	34081
@NP	the lesion	34081
@NP	cavity -LRB- Figs. 1C , D , 2C , D -RRB-	34104
@NP	cavity	34104
@NP	Figs. 1C	34112
@NP	D , 2C , D	34121
@NP	this reduction of the lesion area by OECs	34140
@NP	this reduction	34140
@NP	the lesion area by OECs	34158
@NP	the lesion area	34158
@NP	OECs	34177
@NP	significance	34196
@NP	the direct comparison of the veh-DMEM control group	34212
@NP	the direct comparison	34212
@NP	the veh-DMEM control group	34237
@NP	the other OEC-treated groups	34269
@NP	Fig. 2B ; P = 0.07 for veh-OEC ; P = 0.11 for cAMP-OEC ; P = 0.11 for OEC	34299
@NP	Fig. 2B	34299
@NP	P = 0.07 for veh-OEC ; P = 0.11 for cAMP-OEC ; P = 0.11 for OEC	34308
@NP	P = 0.07 for veh-OEC	34308
@NP	P = 0.07	34308
@NP	P	34308
@NP	0.07	34312
@NP	veh-OEC	34321
@NP	P = 0.11 for cAMP-OEC	34330
@NP	P = 0.11	34330
@NP	P	34330
@NP	0.11	34334
@NP	cAMP-OEC	34343
@NP	P = 0.11 for OEC	34353
@NP	P = 0.11	34353
@NP	P	34353
@NP	0.11	34357
@NP	OEC	34366
@NP	P = 0.33 for rolip-OEC groups	34371
@NP	P = 0.33	34371
@NP	P	34371
@NP	0.33	34375
@NP	rolip-OEC groups	34384
@NP	the combination of OECs with either cAMP-elevating strategy	34414
@NP	the combination	34414
@NP	OECs	34433
@NP	cAMP-elevating strategy	34450
@NP	the trend of the OECs	34498
@NP	the trend	34498
@NP	the OECs	34511
@NP	lesion area -LRB- Fig. 2B -RRB-	34530
@NP	lesion area	34530
@NP	Fig. 2B	34543
@NP	an increase in graft size	34561
@NP	an increase	34561
@NP	graft size	34576
@NP	the size	34605
@NP	the lesion area -LRB- i.e. , disrupted spinal cord cytoarchitecture -RRB-	34617
@NP	the lesion area	34617
@NP	i.e. , disrupted spinal cord cytoarchitecture	34634
@NP	i.e.	34634
@NP	spinal cord cytoarchitecture	34650
@NP	we	34681
@NP	the OEC graft size	34695
@NP	cross-sectional area of the GFP positive cells	34726
@NP	cross-sectional area	34726
@NP	the GFP positive cells	34750
@NP	rolipram treatment	34780
@NP	a strong trend	34809
@NP	increased graft size	34831
@NP	from 3.64 ± 1.1 to 5.5 ± 0.63 SEM , P = 0.07 , Student 's t-test ; Fig. 3J	34853
@NP	3.64	34858
@NP	± 1.1 to 5.5 ± 0.63 SEM , P = 0.07 , Student 's t-test ; Fig. 3J	34863
@NP	± 1.1 to 5.5 ± 0.63 SEM , P = 0.07 , Student 's t-test	34863
@NP	± 1.1 to 5.5 ± 0.63 SEM	34863
@NP	P = 0.07	34888
@NP	P	34888
@NP	0.07	34892
@NP	Student 's t-test	34898
@NP	Student 's	34898
@NP	Fig. 3J	34916
@NP	The density	34926
@NP	GFP-positive cells	34941
@NP	the two injection sites	34968
@NP	1.5 mm rostral to 1.5 mm caudal to the injury	34998
@NP	1.5 mm rostral	34998
@NP	1.5 mm caudal to the injury	35016
@NP	1.5 mm caudal	35016
@NP	the injury	35033
@NP	the systemic rolipram-treatment group -LRB- Fig. 3I -RRB-	35073
@NP	the systemic rolipram-treatment group	35073
@NP	Fig. 3I	35112
@NP	An increase in density of the GFP1 OECs	35122
@NP	An increase	35122
@NP	density of the GFP1 OECs	35137
@NP	density	35137
@NP	the GFP1 OECs	35148
@NP	cell body treatment with dbcAMP -LRB- Fig. 3C -RRB-	35181
@NP	cell body treatment	35181
@NP	dbcAMP -LRB- Fig. 3C -RRB-	35206
@NP	dbcAMP	35206
@NP	Fig. 3C	35214
@NP	this increased OEC density in the systemic rolipram-treatment group	35232
@NP	this increased OEC density	35232
@NP	the systemic rolipram-treatment group	35262
@NP	no cellular proliferation	35301
@NP	the end of the experimental period	35343
@NP	the end	35343
@NP	the experimental period	35354
@NP	Ki67 immunostaining -LRB- Supp	35381
@NP	Ki67	35381
@NP	immunostaining -LRB- Supp	35386
@NP	Info .	35408
@NP	Fig.	35414
@NP	5 ; see	35419
@NP	5	35419
@NP	Discussion for further details	35426
@NP	Discussion	35426
@NP	further details	35441
@NP	The majority of the transplanted OECs	35459
@NP	The majority	35459
@NP	the transplanted OECs	35475
@NP	a spindle-shaped	35501
@NP	morphology	35529
@NP	the cell body or systemic treatments -LRB- top panels in Fig. 3 -RRB-	35554
@NP	the cell body	35554
@NP	systemic treatments -LRB- top panels in Fig. 3 -RRB-	35571
@NP	systemic treatments	35571
@NP	top panels in Fig. 3	35592
@NP	top panels	35592
@NP	Fig. 3	35606
@NP	Most OECs	35615
@NP	cellular strands that had a random orientation in the lesion epicenter	35641
@NP	cellular strands	35641
@NP	a random orientation in the lesion epicenter	35667
@NP	a random orientation	35667
@NP	the lesion epicenter	35691
@NP	rostrocaudal orientation	35728
@NP	the host white matter with finger-like processes	35758
@NP	the host white matter	35758
@NP	finger-like processes	35785
@NP	Double immunostaining for axonal profiles	35808
@NP	Double immunostaining	35808
@NP	axonal profiles	35834
@NP	these strands	35864
@NP	axonal profiles of all calibers -LRB- bottom panels in Fig. 3 -RRB-	35896
@NP	axonal profiles	35896
@NP	all calibers -LRB- bottom panels in Fig. 3 -RRB-	35915
@NP	all calibers	35915
@NP	bottom panels in Fig. 3	35929
@NP	bottom panels	35929
@NP	Fig. 3	35946
@NP	addition	35958
@NP	we	35968
@NP	OECs	35998
@NP	large numbers of host Schwann cells	36011
@NP	large numbers	36011
@NP	host Schwann cells	36028
@NP	newly forming blood vessels	36052
@NP	these strands	36085
@NP	much	36108
@NP	the GFP-negative spaces in these transplants -LRB- Ramer et al. , 2004a -RRB-	36116
@NP	the GFP-negative spaces	36116
@NP	these transplants -LRB- Ramer et al. , 2004a -RRB-	36143
@NP	these transplants	36143
@NP	Ramer	36162
@NP	et al. , 2004a	36168
@NP	et al.	36168
@NP	2004a	36176
@NP	Axonal Regeneration We	36184
@NP	the regeneration/sprouting of axons	36221
@NP	the regeneration/sprouting	36221
@NP	axons	36251
@NP	these LP-OEC-filled lesion sites	36270
@NP	various axonal populations	36313
@NP	we	36341
@NP	antibodies	36349
@NP	both neurofilament 200 and bIII-tubulin	36364
@NP	both neurofilament 200	36364
@NP	bIII-tubulin	36391
@NP	their density	36419
@NP	the OEC-filled lesion site	36440
@NP	Fig. 4A , D	36468
@NP	Fig. 4A	36468
@NP	D	36476
@NP	The systemic treatment with rolipram	36480
@NP	The systemic treatment	36480
@NP	rolipram	36508
@NP	the axonal density	36541
@NP	the lesion site -LRB- Fig. 4D -- F -RRB-	36567
@NP	the lesion site	36567
@NP	Fig. 4D -- F	36584
@NP	Fig. 4D	36584
@NP	F	36592
@NP	the localized cell body treatment of the red nucleus with dbcAMP	36604
@NP	the localized cell body treatment	36604
@NP	the red nucleus with dbcAMP	36641
@NP	the red nucleus	36641
@NP	dbcAMP	36662
@NP	no significant effects on the density of axonal sprouts -LRB- Fig. 4A -- C -RRB-	36673
@NP	no significant effects	36673
@NP	the density of axonal sprouts -LRB- Fig. 4A -- C -RRB-	36699
@NP	the density	36699
@NP	axonal sprouts -LRB- Fig. 4A -- C -RRB-	36714
@NP	axonal sprouts	36714
@NP	Fig. 4A -- C	36730
@NP	Fig. 4A	36730
@NP	C	36738
@NP	levels of GAP-43 and Ta1-tubulin mRNA expression	36751
@NP	levels	36751
@NP	GAP-43 and Ta1-tubulin mRNA expression	36761
@NP	injured rubrospinal neurons	36818
@NP	local infusion of dbcAMP in our preliminary studies	36851
@NP	local infusion	36851
@NP	dbcAMP in our preliminary studies	36869
@NP	dbcAMP	36869
@NP	our preliminary studies	36879
@NP	Supp	36904
@NP	Info .	36910
@NP	Fig. 3	36916
@NP	Fig.	36916
@NP	3	36921
@NP	this absence of an effect	36925
@NP	this absence	36925
@NP	an effect	36941
@NP	overall axonal density	36954
@NP	any effect on rubrospinal axons	37007
@NP	any effect	37007
@NP	rubrospinal axons	37021
@NP	a cell body treatment	37042
@NP	the many other axons of various origins	37091
@NP	the many other axons	37091
@NP	various origins	37115
@NP	the lesion site that also stain for neurofilament 200 and bIII-tubulin	37138
@NP	the lesion site	37138
@NP	neurofilament 200 and bIII-tubulin	37174
@NP	neurofilament 200	37174
@NP	bIII-tubulin	37196
@NP	We	37210
@NP	the sprouting/regeneration	37235
@NP	anterogradely traced rubrospinal axons into / through this spinal bridge of OECs	37265
@NP	anterogradely	37265
@NP	rubrospinal axons	37286
@NP	this spinal bridge	37318
@NP	OECs	37340
@NP	any rubrospinal axon growth	37366
@NP	the lesion in any treatment group	37401
@NP	the lesion	37401
@NP	any treatment group	37415
@NP	some rubrospinal axons	37445
@NP	close association with rostral OEC grafts	37476
@NP	close association	37476
@NP	rostral OEC grafts	37499
@NP	they	37519
@NP	engrafted OEC transplants bridging the lesion site itself	37550
@NP	engrafted OEC transplants	37550
@NP	the lesion site	37585
@NP	itself	37601
@NP	in Figure 1C and in our camera lucida drawings	37618
@NP	Figure 1C	37621
@NP	our camera lucida	37638
@NP	Info .	37672
@NP	4	37683
@NP	neither cell body treatment	37698
@NP	the red nucleus with dbcAMP nor systemic treatment with rolipram	37729
@NP	the red nucleus	37729
@NP	dbcAMP nor systemic treatment with rolipram	37750
@NP	dbcAMP	37750
@NP	systemic treatment with rolipram	37761
@NP	systemic treatment	37761
@NP	rolipram	37785
@NP	regeneration of rubrospinal axons	37803
@NP	regeneration	37803
@NP	rubrospinal axons	37819
@NP	the OEC transplants -LRB- Fig. 1D , Supp	37845
@NP	the OEC transplants	37845
@NP	Fig. 1D	37866
@NP	Supp	37875
@NP	Info .	37881
@NP	2C , 4	37893
@NP	2C	37893
@NP	4	37897
@NP	there	37910
@NP	pronounced differences in the morphology of the rubrospinal tract rostral	37921
@NP	pronounced differences	37921
@NP	the morphology of the rubrospinal tract rostral	37947
@NP	the morphology	37947
@NP	the rubrospinal tract rostral	37965
@NP	the site of injury	37998
@NP	the site	37998
@NP	injury	38010
@NP	Rubrospinal axons	38018
@NP	axotomy -LRB- Ye and Houle , 1997 -RRB-	38064
@NP	axotomy	38064
@NP	Ye and Houle , 1997	38073
@NP	Ye	38073
@NP	Houle , 1997	38080
@NP	Houle	38080
@NP	1997	38087
@NP	we	38098
@NP	their dystrophic endings	38107
@NP	1,700 µm -LRB- 6323 µm -RRB-	38141
@NP	6323 µm	38151
@NP	rostral	38160
@NP	the lesion epicenter in our control condition	38173
@NP	the lesion epicenter	38173
@NP	our control condition	38197
@NP	DMEM in Fig. 1A	38225
@NP	DMEM	38225
@NP	Fig. 1A	38233
@NP	Supp	38245
@NP	Info .	38251
@NP	Fig. 4 ; Bretzner et al. , 2008 -RRB- .	38257
@NP	Fig. 4	38257
@NP	Bretzner et al. , 2008 -RRB-	38265
@NP	Bretzner	38265
@NP	et al.	38274
@NP	2008	38282
@NP	This retraction of rubrospinal axons	38289
@NP	This retraction	38289
@NP	rubrospinal axons	38308
@NP	all treatment groups	38358
@NP	veh-DMEM -LRB- Fig. 5A , Supp	38393
@NP	veh-DMEM	38393
@NP	Fig. 5A	38403
@NP	Supp	38412
@NP	Info .	38418
@NP	4	38429
@NP	It	38433
@NP	most anterogradely traced axons	38462
@NP	most	38462
@NP	axons	38488
@NP	the host tissue	38507
@NP	proximity	38558
@NP	the transplanted OECs	38573
@NP	the injections sites -LRB- Fig. 1D , Supp	38603
@NP	the injections sites	38603
@NP	Fig. 1D	38625
@NP	Supp	38634
@NP	Info .	38640
@NP	2C , 4	38652
@NP	2C	38652
@NP	4	38656
@NP	The straight course of many of these axons	38660
@NP	The straight course	38660
@NP	many of these axons	38683
@NP	many	38683
@NP	these axons	38691
@NP	the interpretation	38712
@NP	these axons	38736
@NP	it	38775
@NP	retracting axons	38807
@NP	newly sprouted and subsequently frustrated axons	38843
@NP	These group differences in rubrospinal axon profiles at the rostral lesion edge	38893
@NP	These group differences	38893
@NP	rubrospinal axon profiles at the rostral lesion edge	38920
@NP	rubrospinal axon profiles	38920
@NP	the rostral lesion edge	38949
@NP	differences	38989
@NP	the efficacy	39004
@NP	anterograde	39020
@NP	there	39052
@NP	no significant differences	39063
@NP	the number of traced rubrospinal axons at the C2 level of the spinal cord	39093
@NP	the number	39093
@NP	traced rubrospinal axons at the C2 level of the spinal cord	39107
@NP	traced rubrospinal axons	39107
@NP	the C2 level of the spinal cord	39135
@NP	the C2 level	39135
@NP	the spinal cord	39151
@NP	data not shown	39168
@NP	data	39168
@NP	We	39185
@NP	the possibility	39202
@NP	our treatment	39223
@NP	the terminal branching of the RS axons within the cervical gray matter	39257
@NP	the terminal branching of the RS axons	39257
@NP	the RS	39283
@NP	the cervical gray matter	39303
@NP	It	39329
@NP	rubrospinal axons	39352
@NP	spinal interneurons that bypass the lesion site and thereby contribute	39389
@NP	spinal interneurons	39389
@NP	the lesion site	39421
@NP	functional recovery	39463
@NP	corticospinal axons -LRB- Bareyre et al. , 2004 ; Vavrek et al. , 2006 -RRB-	39517
@NP	corticospinal axons	39517
@NP	Bareyre	39538
@NP	et al. , 2004 ; Vavrek et al. , 2006	39546
@NP	et al.	39546
@NP	2004 ; Vavrek et al.	39554
@NP	2004	39554
@NP	Vavrek et al.	39560
@NP	Vavrek	39560
@NP	et al.	39567
@NP	2006	39575
@NP	the density of rubrospinal axon profiles	39589
@NP	the density	39589
@NP	rubrospinal axon profiles	39604
@NP	the gray matter on cervical cross-sections	39650
@NP	the gray matter	39650
@NP	cervical cross-sections	39669
@NP	C2 -LRB- i.e. , more than a segment rostral to the lesion -RRB-	39696
@NP	C2	39696
@NP	a segment rostral to the lesion	39716
@NP	a segment rostral	39716
@NP	the lesion	39737
@NP	the number	39767
@NP	cross-sectioned axons	39789
@NP	the rubrospinal tract	39814
@NP	this level	39839
@NP	axon profile index ; Fig. 5C	39862
@NP	axon profile index	39862
@NP	Fig. 5C	39882
@NP	There	39892
@NP	no significant change in axon profiles	39902
@NP	no significant change	39902
@NP	axon profiles	39927
@NP	any treatment group	39944
@NP	the OEC-rolipram group	39974
@NP	significantly more branches	40004
@NP	the rolipram-DMEM treatment group	40037
@NP	a direct paired t-test -LRB- P < 0.006 -RRB-	40074
@NP	a direct paired t-test	40074
@NP	P < 0.006	40098
@NP	P	40098
@NP	< 0.006	40100
@NP	<	40100
@NP	0.006	40102
@NP	Functional Outcomes To understand the behavioral effects of our treatments	40110
@NP	Functional Outcomes	40110
@NP	the behavioral effects of our treatments	40144
@NP	the behavioral effects	40144
@NP	our treatments	40170
@NP	we	40186
@NP	the sensory thresholds	40196
@NP	thermal and mechanical stimulations of the forepaws -LRB- Fig. 6 , Supp	40222
@NP	thermal and mechanical stimulations	40222
@NP	the forepaws -LRB- Fig. 6 , Supp	40261
@NP	the forepaws	40261
@NP	Fig. 6	40275
@NP	Supp	40283
@NP	Info .	40289
@NP	6	40300
@NP	response to thermal stimulation	40307
@NP	response	40307
@NP	thermal stimulation	40319
@NP	the withdrawal latency in the left forepaw -LRB- side of injury -RRB-	40340
@NP	the withdrawal latency	40340
@NP	the left forepaw -LRB- side of injury -RRB-	40366
@NP	the left forepaw	40366
@NP	side of injury	40384
@NP	side	40384
@NP	injury	40392
@NP	all experimental groups	40424
@NP	the veh-DMEM controls -LRB- top panels in Fig. 6 -RRB-	40462
@NP	the veh-DMEM controls	40462
@NP	top panels in Fig. 6	40485
@NP	top panels	40485
@NP	Fig. 6	40499
@NP	Shorter withdrawal latencies	40508
@NP	significance	40545
@NP	the OEC	40566
@NP	OEC-rolipram groups -LRB- weeks 3 and 4 , respectively ; Fig. 6C -RRB-	40578
@NP	OEC-rolipram groups	40578
@NP	weeks 3 and 4 , respectively ; Fig. 6C	40599
@NP	weeks 3 and 4 , respectively	40599
@NP	weeks 3 and 4	40599
@NP	Fig. 6C	40628
@NP	the contralateral right forepaw	40652
@NP	veh-OEC and OEC transplants	40685
@NP	the withdrawal latency	40730
@NP	treatment scenarios	40763
@NP	bottom panels in Fig. 6	40784
@NP	bottom panels	40784
@NP	Fig. 6	40801
@NP	these observations	40819
@NP	transplantation of OECs	40851
@NP	transplantation	40851
@NP	OECs	40870
@NP	thermal hypersensitivity of the forepaws	40890
@NP	thermal hypersensitivity	40890
@NP	the forepaws	40918
@NP	We	40932
@NP	the mechanical thresholds	40949
@NP	no significant changes	40985
@NP	the cell body treatment with cAMP	41032
@NP	the cell body treatment	41032
@NP	cAMP	41061
@NP	Info .	41073
@NP	6	41084
@NP	technical reasons	41107
@NP	we	41126
@NP	changes for the systemic treatment	41158
@NP	changes	41158
@NP	the systemic treatment	41170
@NP	We	41194
@NP	the performance of the left injured forelimb	41211
@NP	the performance	41211
@NP	the left injured forelimb	41230
@NP	the cylinder test -LRB- top panels in Fig. 7 -RRB-	41259
@NP	the cylinder test	41259
@NP	top panels in Fig. 7	41278
@NP	top panels	41278
@NP	Fig. 7	41292
@NP	the food-pellet-reaching task -LRB- bottom panels in Fig. 7 -RRB-	41311
@NP	the food-pellet-reaching task	41311
@NP	bottom panels in Fig. 7	41342
@NP	bottom panels	41342
@NP	Fig. 7	41359
@NP	the cylinder test , before dorsolateral funiculus lesion	41371
@NP	the cylinder test	41371
@NP	dorsolateral funiculus lesion	41397
@NP	all animals	41428
@NP	75 % of the time with the `` left and both ''	41453
@NP	75 %	41453
@NP	the time with the `` left and both ''	41460
@NP	the time	41460
@NP	the `` left and both	41474
@NP	the `` left	41474
@NP	forelimbs during vertical exploration -LRB- Liu et al. , 1999 -RRB-	41496
@NP	forelimbs	41496
@NP	vertical exploration	41513
@NP	Liu	41535
@NP	et al. , 1999	41539
@NP	et al.	41539
@NP	1999	41547
@NP	spinal cord injury	41560
@NP	the usage of the left plus both forelimbs for the control group	41580
@NP	the usage of the left	41580
@NP	the usage	41580
@NP	the left	41593
@NP	both forelimbs for the control group	41607
@NP	both forelimbs	41607
@NP	the control group	41626
@NP	vehicle-DMEM	41645
@NP	30 -- 40 %	41670
@NP	30	41670
@NP	baseline	41699
@NP	the 4 weeks of assessment	41713
@NP	the 4 weeks	41713
@NP	assessment	41728
@NP	all individual treatments as well as the dbcAMP-OEC combination	41749
@NP	all individual treatments	41749
@NP	all	41749
@NP	individual treatments	41753
@NP	the dbcAMP-OEC combination	41786
@NP	a usage of left	41825
@NP	a usage	41825
@NP	left	41836
@NP	both forelimbs of about 50 %	41846
@NP	both forelimbs	41846
@NP	50 %	41870
@NP	only the combination of OEC transplant with systemic infusion of rolipram	41875
@NP	only the combination	41875
@NP	OEC transplant with systemic infusion of rolipram	41899
@NP	OEC transplant	41899
@NP	systemic infusion of rolipram	41919
@NP	systemic infusion	41919
@NP	rolipram	41940
@NP	significance	41957
@NP	a usage level of 59 %	41973
@NP	a usage level	41973
@NP	59 %	41990
@NP	There	41995
@NP	no significant differences	42006
@NP	therapies in the food - pellet-reaching task -LRB- bottom panels in Fig. 7 -RRB-	42041
@NP	therapies	42041
@NP	the food - pellet-reaching task -LRB- bottom panels in Fig. 7 -RRB-	42054
@NP	the food	42054
@NP	pellet-reaching task	42064
@NP	bottom panels in Fig. 7	42086
@NP	bottom panels	42086
@NP	Fig. 7	42103
@NP	summary	42115
@NP	OEC transplants	42133
@NP	the thermal hypersensitivity of the forepaws	42159
@NP	the thermal hypersensitivity	42159
@NP	the forepaws	42191
@NP	their combination with systemic infusion of rolipram	42205
@NP	their combination	42205
@NP	systemic infusion of rolipram	42228
@NP	systemic infusion	42228
@NP	rolipram	42249
@NP	the return of usage of the left injured forelimb	42267
@NP	the return	42267
@NP	usage of the left injured forelimb	42281
@NP	usage	42281
@NP	the left injured forelimb	42290
@NP	vertical exploration in a cylinder	42323
@NP	vertical exploration	42323
@NP	a cylinder	42347
@NP	Correlations	42359
@NP	Anatomical and Behavioral Measurements	42380
@NP	most studies of the injured spinal cord	42427
@NP	most studies	42427
@NP	the injured spinal cord	42443
@NP	we	42468
@NP	the mechanisms	42493
@NP	anatomical parameters	42517
@NP	the improvement of functional recovery	42553
@NP	the improvement	42553
@NP	functional recovery	42572
@NP	we	42599
@NP	correlation analyses of forelimb usage , improved by rolipram plus OECs ,	42612
@NP	correlation analyses	42612
@NP	forelimb usage , improved by rolipram plus OECs ,	42636
@NP	forelimb usage	42636
@NP	rolipram plus OECs	42664
@NP	rolipram	42664
@NP	OECs	42678
@NP	our anatomical measurements	42689
@NP	This	42718
@NP	any causality	42738
@NP	possible links	42765
@NP	example	42785
@NP	GFAP expression	42802
@NP	better transplant integration	42835
@NP	axons to cross the transplant -- host interface	42887
@NP	the transplant -- host interface	42902
@NP	the transplant	42902
@NP	host interface	42917
@NP	We	42933
@NP	a significant inverse correlation	42942
@NP	the percentage of usage of the left forelimb	42984
@NP	the percentage	42984
@NP	usage of the left forelimb	43002
@NP	usage	43002
@NP	the left forelimb	43011
@NP	vertical exploration in the cylinder test	43036
@NP	vertical exploration	43036
@NP	the cylinder test	43060
@NP	the immunoreactivity for GFAP -LRB- R < 20.35 , P < 0.03 -RRB-	43082
@NP	the immunoreactivity	43082
@NP	GFAP -LRB- R < 20.35 , P < 0.03 -RRB-	43107
@NP	GFAP	43107
@NP	R < 20.35	43113
@NP	R	43113
@NP	< 20.35	43115
@NP	<	43115
@NP	20.35	43117
@NP	P < 0.03	43124
@NP	P	43124
@NP	< 0.03	43126
@NP	<	43126
@NP	0.03	43128
@NP	i.e.	43135
@NP	rats using their left forelimb more	43141
@NP	rats	43141
@NP	their	43152
@NP	less GFAP immunoreactivity	43198
@NP	addition	43229
@NP	there	43239
@NP	a correlation	43249
@NP	the percentage of usage of the left forelimb in the cylinder test	43271
@NP	the percentage	43271
@NP	usage of the left forelimb in the cylinder test	43289
@NP	usage	43289
@NP	the left forelimb in the cylinder test	43298
@NP	the left forelimb	43298
@NP	the cylinder test	43319
@NP	the branching	43342
@NP	rubrospinal axons rostral	43359
@NP	the lesion site in the animals treated with OECs and rolipram	43388
@NP	the lesion site	43388
@NP	the animals treated with OECs and rolipram	43407
@NP	the animals	43407
@NP	OECs and rolipram	43432
@NP	R < 0.76	43451
@NP	R	43451
@NP	< 0.76	43453
@NP	<	43453
@NP	0.76	43455
@NP	P < 0.078	43461
@NP	P	43461
@NP	< 0.078	43463
@NP	<	43463
@NP	0.078	43465
@NP	DISCUSSION	43474
@NP	we	43490
@NP	our previous work -LRB- Ramer et al. , 2004a ; Richter et al. , 2005 -RRB-	43519
@NP	our previous work	43519
@NP	Ramer	43538
@NP	et al. , 2004a ; Richter et al. , 2005	43544
@NP	et al.	43544
@NP	2004a ; Richter et al.	43552
@NP	2004a	43552
@NP	Richter et al.	43559
@NP	Richter	43559
@NP	et al.	43567
@NP	2005	43575
@NP	neonatal mouse lamina	43582
@NP	the injured rat spinal cord	43641
@NP	the lesion site	43677
@NP	cavitation	43704
@NP	the host astrocytic hypertrophy	43731
@NP	massive	43780
@NP	the injury site	43810
@NP	Transplantation	43827
@NP	OECs with or without dbcAMP to the red nucleus or systemic rolipram	43846
@NP	OECs	43846
@NP	dbcAMP to the red nucleus or systemic rolipram	43867
@NP	dbcAMP	43867
@NP	the red nucleus or systemic rolipram	43877
@NP	the red nucleus	43877
@NP	systemic rolipram	43896
@NP	the axonal dieback of rubrospinal axons	43922
@NP	the axonal dieback	43922
@NP	rubrospinal axons	43944
@NP	their regeneration	43984
@NP	the injury site	44019
@NP	rolipram treatment	44041
@NP	the density of the transplanted OECs	44069
@NP	the density	44069
@NP	the transplanted OECs	44084
@NP	the density of axonal sprouting into the OEC transplants	44125
@NP	the density	44125
@NP	axonal sprouting into the OEC transplants	44140
@NP	axonal	44140
@NP	the OEC transplants	44162
@NP	The combined treatment group of OECs with rolipram	44183
@NP	The combined treatment group	44183
@NP	OECs with rolipram	44215
@NP	OECs	44215
@NP	rolipram	44225
@NP	significant recovery of forelimb usage	44241
@NP	significant recovery	44241
@NP	forelimb usage	44265
@NP	a cylinder test	44283
@NP	the levels of controls	44322
@NP	the levels	44322
@NP	controls	44336
@NP	this functional improvement	44356
@NP	an	44404
@NP	astrocytic hypertrophy and an enhanced rubrospinal branching rotral	44418
@NP	astrocytic hypertrophy	44418
@NP	an enhanced rubrospinal branching rotral	44445
@NP	the lesion site	44489
@NP	this latter combination group as well as OECs alone	44520
@NP	this latter combination group	44520
@NP	OECs alone	44561
@NP	OECs	44561
@NP	lowered thermal thresholds	44582
@NP	sensory testing of the forepaw	44614
@NP	sensory testing	44614
@NP	the forepaw	44633
@NP	the side of injury	44648
@NP	the side	44648
@NP	injury	44660
@NP	thermal allodynia	44682
@NP	Two treatments	44701
@NP	the aim of increasing cAMP	44733
@NP	the aim	44733
@NP	increasing cAMP	44744
@NP	the level of the red nucleus by dbcAMP infusion	44779
@NP	the level	44779
@NP	the red nucleus by dbcAMP infusion	44792
@NP	the red nucleus	44792
@NP	dbcAMP infusion	44811
@NP	rolipram , a phosphodiesterase inhibitor ,	44848
@NP	rolipram	44848
@NP	a phosphodiesterase inhibitor	44858
@NP	osmotic minipumps	44916
@NP	Infusion of dbcAMP	44935
@NP	Infusion	44935
@NP	dbcAMP	44947
@NP	the retraction of rubrospinal axons	44971
@NP	the retraction	44971
@NP	rubrospinal axons	44989
@NP	the injury site	45012
@NP	the effect	45043
@NP	any of the other histopathological parameters at the lesion site	45057
@NP	any	45057
@NP	the other histopathological parameters at the lesion site	45064
@NP	the other histopathological parameters	45064
@NP	the lesion site	45106
@NP	behavior	45136
@NP	significance	45159
@NP	It	45173
@NP	the prevention of retraction/dieback	45204
@NP	the prevention	45204
@NP	retraction/dieback	45222
@NP	axons	45259
@NP	both	45277
@NP	parallel	45295
@NP	the straight course and larger caliber of many of these axons	45314
@NP	the straight course	45314
@NP	larger caliber of many of these axons	45338
@NP	larger caliber	45338
@NP	many of these axons	45356
@NP	many	45356
@NP	these axons	45364
@NP	these	45389
@NP	This	45415
@NP	the dbcAMP treatment of the rubrospinal neurons	45435
@NP	the dbcAMP treatment	45435
@NP	the rubrospinal neurons	45459
@NP	a neuroprotective effect on their axons	45487
@NP	a neuroprotective effect	45487
@NP	their axons	45515
@NP	Several specific downstream effectors	45528
@NP	cAMP treatment	45593
@NP	dorsal root ganglion cells	45611
@NP	a positive role	45648
@NP	axonal growth	45667
@NP	Cai et al. , 1999 ; Neumann et al. , 2002 ; Qiu et al. , 2002	45682
@NP	Cai	45682
@NP	et al. , 1999 ; Neumann et al. , 2002 ; Qiu et al. , 2002	45686
@NP	et al. , 1999	45686
@NP	et al.	45686
@NP	1999	45694
@NP	Neumann et al. , 2002	45700
@NP	Neumann	45700
@NP	et al. , 2002	45708
@NP	et al.	45708
@NP	2002	45716
@NP	Qiu et al. , 2002	45722
@NP	Qiu	45722
@NP	et al. , 2002	45726
@NP	et al.	45726
@NP	2002	45734
@NP	we	45752
@NP	increased levels of GAP-43 and Ta1-tubulin mRNA expression	45761
@NP	increased levels	45761
@NP	GAP-43 and Ta1-tubulin mRNA expression	45781
@NP	injured rubrospinal neurons	45823
@NP	local infusion of dbcAMP -LRB- Supp	45856
@NP	local infusion	45856
@NP	dbcAMP -LRB- Supp	45874
@NP	Info .	45888
@NP	3	45899
@NP	It	45903
@NP	these latter regeneration-associated gene products	45923
@NP	the maintainance of the axonal stumps	45993
@NP	the maintainance	45993
@NP	the axonal stumps	46013
@NP	their regeneration	46041
@NP	The local infusion of dbcAMP near the rubrospinal cell bodies	46081
@NP	The local infusion	46081
@NP	dbcAMP near the rubrospinal cell bodies	46103
@NP	dbcAMP	46103
@NP	the rubrospinal cell bodies	46115
@NP	some inflammation and tissue damage	46162
@NP	the infusion site	46205
@NP	a translational perspective	46232
@NP	a proof of principle	46278
@NP	a proof	46278
@NP	principle	46289
@NP	Local tissue damage by dbcAMP	46300
@NP	Local tissue damage	46300
@NP	dbcAMP	46323
@NP	others -LRB- Lu and Richardson , 1991 ; Fouad et al. , 2009 -RRB-	46360
@NP	others	46360
@NP	Lu and Richardson	46368
@NP	Lu	46368
@NP	Richardson	46375
@NP	1991 ; Fouad et al. , 2009	46387
@NP	1991	46387
@NP	Fouad et al. , 2009	46393
@NP	Fouad	46393
@NP	et al. , 2009	46399
@NP	et al.	46399
@NP	2009	46407
@NP	It	46414
@NP	the systemic treatment with rolipram , a clinically used drug ,	46453
@NP	the systemic treatment	46453
@NP	rolipram , a clinically used drug ,	46481
@NP	rolipram	46481
@NP	a clinically used drug	46491
@NP	rubrospinal axon retraction	46536
@NP	combination with OEC transplantation	46568
@NP	combination	46568
@NP	OEC transplantation	46585
@NP	rolipram treatment	46606
@NP	several beneficial effects	46629
@NP	any of the other treatment groups	46669
@NP	any	46669
@NP	the other treatment groups	46676
@NP	these	46704
@NP	the density of the OECs	46733
@NP	the density	46733
@NP	the OECs	46748
@NP	the transplants	46760
@NP	increasing axonal density in the lesion	46780
@NP	increasing axonal density	46780
@NP	the lesion	46809
@NP	motor recovery of forelimb usage	46824
@NP	motor recovery	46824
@NP	forelimb usage	46842
@NP	we	46867
@NP	survival	46889
@NP	ongoing proliferative effects of rolipram -LRB- Alexander et al. , 2002 -RRB-	46903
@NP	ongoing proliferative effects	46903
@NP	rolipram -LRB- Alexander et al. , 2002 -RRB-	46936
@NP	rolipram	46936
@NP	Alexander	46946
@NP	et al. , 2002	46956
@NP	et al.	46956
@NP	2002	46964
@NP	we	46971
@NP	no evidence	46980
@NP	any proliferation	46996
@NP	the end	47017
@NP	the experimental period	47028
@NP	by Ki67 immunostaining	47063
@NP	Info .	47093
@NP	5	47104
@NP	a cAMP elevation	47127
@NP	GFAP expression	47177
@NP	OECs	47196
@NP	their morphology	47215
@NP	an astrocyte-like type within 1 day	47235
@NP	an astrocyte-like type	47235
@NP	1 day	47265
@NP	Doucette and Devon , 1995 ; Vincent et al. , 2003	47281
@NP	Doucette and Devon	47281
@NP	1995 ; Vincent et al.	47301
@NP	1995	47301
@NP	Vincent et al.	47307
@NP	Vincent	47307
@NP	et al.	47315
@NP	2003	47323
@NP	our transplanted OECs	47330
@NP	an elongated , spindle-shape morphology	47362
@NP	an	47362
@NP	spindle-shape morphology	47376
@NP	GFAP levels	47421
@NP	immunohistochemistry at the end of the experimental period in the current study	47447
@NP	immunohistochemistry	47447
@NP	the end of the experimental period in the current study	47471
@NP	the end	47471
@NP	the experimental period in the current study	47482
@NP	the experimental period	47482
@NP	the current study	47509
@NP	rolipram	47537
@NP	this time	47571
@NP	we	47585
@NP	a proliferative effect of rolipram	47606
@NP	a proliferative effect	47606
@NP	rolipram	47632
@NP	some changes in OECs morphology and transient GFAP expression	47652
@NP	some changes	47652
@NP	OECs morphology and transient GFAP expression	47668
@NP	OECs morphology	47668
@NP	transient GFAP expression	47688
@NP	the earlier treatment stage	47717
@NP	a higher OEC density in the transplants	47759
@NP	a higher OEC density	47759
@NP	the transplants	47783
@NP	the amount of trophic factors produced	47819
@NP	the amount	47819
@NP	trophic factors produced	47833
@NP	trophic factors	47833
@NP	olfactory bulb-derived OECs	47863
@NP	a source	47913
@NP	trophic factors	47925
@NP	Boruch	47942
@NP	et al. , 2001	47949
@NP	et al.	47949
@NP	2001	47957
@NP	Lipson et al. , 2003	47963
@NP	Lipson	47963
@NP	et al. , 2003	47970
@NP	et al.	47970
@NP	2003	47978
@NP	Sasaki et al. , 2006b	47984
@NP	Sasaki	47984
@NP	et al. , 2006b	47991
@NP	et al.	47991
@NP	2006b	47999
@NP	Wang et al. , 2006	48006
@NP	Wang	48006
@NP	et al. , 2006	48011
@NP	et al.	48011
@NP	2006	48019
@NP	This in turn	48026
@NP	This	48026
@NP	turn	48034
@NP	stronger effects on the host	48053
@NP	stronger effects	48053
@NP	the host	48073
@NP	spinal cord	48082
@NP	trophic factors	48101
@NP	axonal sprouting and sparing -LRB- Hendriks et al. , 2006 -RRB-	48125
@NP	axonal sprouting and sparing	48125
@NP	axonal	48125
@NP	Hendriks	48155
@NP	et al. , 2006	48164
@NP	et al.	48164
@NP	2006	48172
@NP	cellular excitability	48190
@NP	the absence of rubrospinal axonal regeneration	48224
@NP	the absence	48224
@NP	rubrospinal axonal regeneration	48239
@NP	the systemic combinatorial therapy with OEC-rolipram	48272
@NP	the systemic combinatorial therapy	48272
@NP	OEC-rolipram	48312
@NP	recovery of left forelimb usage	48334
@NP	recovery	48334
@NP	left forelimb usage	48346
@NP	this	48371
@NP	astrocytic hypertrophy	48403
@NP	rubrospinal axons rostral	48452
@NP	the lesion site	48481
@NP	It	48498
@NP	these enhanced branches of rubrospinal axons	48518
@NP	these enhanced branches	48518
@NP	rubrospinal axons	48545
@NP	spinal interneuronal networks	48574
@NP	the lesion in the spared host tissue	48618
@NP	the lesion	48618
@NP	the spared host tissue	48632
@NP	Examples for such mechanisms	48656
@NP	Examples	48656
@NP	such mechanisms	48669
@NP	the injured corticospinal system	48711
@NP	Bareyre	48745
@NP	et al. , 2004 ; Vavrek et al. , 2006	48753
@NP	et al.	48753
@NP	2004 ; Vavrek et al.	48761
@NP	2004	48761
@NP	Vavrek et al.	48767
@NP	Vavrek	48767
@NP	et al.	48774
@NP	2006	48782
@NP	the intact rubrospinal system	48806
@NP	pyramidal tract injury and IN-1 antibody treatment	48855
@NP	Raineteau	48907
@NP	et al. , 2002	48917
@NP	et al.	48917
@NP	2002	48925
@NP	such	48945
@NP	the recovery	48992
@NP	limb usage	49008
@NP	mainly proximal limb muscles innervated from higher cervical spinal cord levels	49035
@NP	mainly proximal limb muscles	49035
@NP	higher cervical spinal cord levels	49080
@NP	they	49120
@NP	distal limb muscles	49144
@NP	the lower spinal cord levels	49187
@NP	there	49228
@NP	no recovery in the food-pellet-reaching test	49238
@NP	no recovery	49238
@NP	the food-pellet-reaching test	49253
@NP	contrast to dorsal root ganglia -LRB- Qiu et al. , 2002 ; Lu et al. , 2004 -RRB-	49287
@NP	contrast	49287
@NP	dorsal root ganglia -LRB- Qiu et al. , 2002 ; Lu et al. , 2004 -RRB-	49299
@NP	dorsal root ganglia	49299
@NP	Qiu	49320
@NP	et al. , 2002 ; Lu et al. , 2004	49324
@NP	et al.	49324
@NP	2002 ; Lu et al.	49332
@NP	2002	49332
@NP	Lu et al.	49338
@NP	Lu	49338
@NP	et al.	49341
@NP	2004	49349
@NP	cell body treatment of the red nucleus	49356
@NP	cell body treatment	49356
@NP	the red nucleus	49379
@NP	axonal regeneration of rubrospinal neurons	49413
@NP	axonal regeneration	49413
@NP	rubrospinal neurons	49436
@NP	cell transplants	49461
@NP	these last neurons	49500
@NP	axotomy than dorsal root ganglia	49548
@NP	axotomy	49548
@NP	dorsal root ganglia	49561
@NP	the absence	49593
@NP	regeneration of rubrospinal tract axons into OECs grafts with either treatments	49608
@NP	regeneration	49608
@NP	rubrospinal tract axons into OECs grafts with either treatments	49624
@NP	rubrospinal tract axons	49624
@NP	OECs grafts	49653
@NP	treatments	49677
@NP	contrast to our earlier results	49698
@NP	contrast	49698
@NP	our earlier results	49710
@NP	peripheral nerve grafts -LRB- Kobayashi et al. , 1997 -RRB-	49735
@NP	peripheral nerve grafts	49735
@NP	Kobayashi	49760
@NP	et al. , 1997	49770
@NP	et al.	49770
@NP	1997	49778
@NP	This	49785
@NP	rubrospinal axons	49804
@NP	OECs grafts	49845
@NP	the OEC	49869
@NP	grafts	49877
@NP	critical factors or spatial alignments	49889
@NP	critical factors	49889
@NP	spatial alignments	49909
@NP	nerve grafts	49942
@NP	Transplant-induced plasticity	49956
@NP	other host	49999
@NP	axonal systems as well , which we left untraced , including the sensory systems	50010
@NP	axonal systems	50010
@NP	we	50040
@NP	the sensory systems	50068
@NP	Our sensory measurements	50089
@NP	the OECs	50127
@NP	a tendency to lower thermal thresholds	50146
@NP	a tendency	50146
@NP	lower thermal thresholds	50160
@NP	this effect	50190
@NP	the combination of OECs	50219
@NP	the combination	50219
@NP	OECs	50238
@NP	rolipram	50248
@NP	This effect	50258
@NP	a higher level of neurotrophins in the injured spinal cord	50286
@NP	a higher level	50286
@NP	neurotrophins in the injured spinal cord	50304
@NP	neurotrophins	50304
@NP	the injured spinal cord	50321
@NP	neurotrophins such as NGF and BDNF	50346
@NP	neurotrophins	50346
@NP	NGF and BDNF	50368
@NP	the sensitization	50417
@NP	dorsal horn neurons	50438
@NP	the spinal cord	50461
@NP	Kerr et al. , 1999 ; Mannion et al. , 1999 ; Heppenstall and Lewin , 2001	50478
@NP	Kerr	50478
@NP	et al. , 1999 ; Mannion et al. , 1999 ; Heppenstall and Lewin , 2001	50483
@NP	et al. , 1999	50483
@NP	et al.	50483
@NP	1999	50491
@NP	Mannion et al. , 1999	50497
@NP	Mannion	50497
@NP	et al. , 1999	50505
@NP	et al.	50505
@NP	1999	50513
@NP	Heppenstall and Lewin , 2001	50519
@NP	Heppenstall and Lewin	50519
@NP	2001	50542
@NP	Olfactory bulb-derived OECs	50549
@NP	the mRNAs for these neurotrophins	50585
@NP	the mRNAs	50585
@NP	these neurotrophins	50599
@NP	the proteins	50632
@NP	Boruch	50646
@NP	et al. , 2001	50653
@NP	et al.	50653
@NP	2001	50661
@NP	Lipson et al. , 2003	50667
@NP	Lipson	50667
@NP	et al. , 2003	50674
@NP	et al.	50674
@NP	2003	50682
@NP	Sasaki et al. , 2006b	50688
@NP	Sasaki	50688
@NP	et al. , 2006b	50695
@NP	et al.	50695
@NP	2006b	50703
@NP	Wang et al. , 2006	50710
@NP	Wang	50710
@NP	et al. , 2006	50715
@NP	et al.	50715
@NP	2006	50723
@NP	Schwann cells	50741
@NP	the spinal cord	50760
@NP	neurotrophin levels	50794
@NP	the lesion site -LRB- Sasaki et al. , 2006b -RRB-	50828
@NP	the lesion site	50828
@NP	Sasaki	50845
@NP	et al. , 2006b	50852
@NP	et al.	50852
@NP	2006b	50860
@NP	similar direct or indirect trophic effects	50881
@NP	similar direct	50881
@NP	indirect trophic effects	50899
@NP	LP-OECs	50945
@NP	we	50958
@NP	their ability to attract endogenous Schwann cells previously	50975
@NP	endogenous Schwann cells	51000
@NP	Ramer	51037
@NP	et al. , 2004a	51043
@NP	et al.	51043
@NP	2004a	51051
@NP	addition	51062
@NP	rolipram	51072
@NP	the release of glutamate	51096
@NP	the release	51096
@NP	glutamate	51111
@NP	the nerve terminals -LRB- Wang , 2006 -RRB-	51124
@NP	the nerve terminals	51124
@NP	Wang	51145
@NP	2006	51151
@NP	this sensitization of sensory neurons	51186
@NP	this sensitization	51186
@NP	sensory neurons	51208
@NP	this	51234
@NP	an enhanced release of glutamate by rubrospinal and other axonal terminals	51255
@NP	an enhanced release	51255
@NP	glutamate by rubrospinal and other axonal terminals	51278
@NP	glutamate	51278
@NP	rubrospinal and other axonal terminals	51291
@NP	the excitability of spinal interneuronal circuits	51351
@NP	the excitability	51351
@NP	spinal interneuronal circuits	51371
@NP	only the combination of OEC with rolipram	51409
@NP	only the combination	51409
@NP	OEC with rolipram	51433
@NP	OEC	51433
@NP	rolipram	51442
@NP	the motor performance	51460
@NP	the cylinder test	51485
@NP	this	51508
@NP	the rubrospinal branching rostral to the lesion site	51540
@NP	the rubrospinal branching rostral	51540
@NP	the lesion site	51577
@NP	summary	51597
@NP	thermal hypersensitivity resulting from the lamina propria-derived OECs	51614
@NP	thermal hypersensitivity	51614
@NP	the lamina propria-derived OECs	51654
@NP	the possibility	51687
@NP	autologous cell transplants	51712
@NP	combination with systemic rolipram infusion	51743
@NP	combination	51743
@NP	systemic rolipram infusion	51760
@NP	regard	51811
@NP	the motor recovery	51821
@NP	the enhanced engrafted cells survival/division	51841
@NP	the axonal regeneration/sprouting into the transplant	51889
@NP	the axonal regeneration/sprouting	51889
@NP	the transplant	51928
@NP	the potential functional sprouting / sparing of rubrospinal tract axons rostral	51948
@NP	sparing of rubrospinal tract axons	51984
@NP	sparing	51984
@NP	rubrospinal tract axons	51995
@NP	the lesion	52030
@NP	the future	52045
@NP	we	52056
@NP	more	52098
@NP	the neural mechanisms	52116
@NP	this functional recovery	52154
@NP	some alternatives	52188
@NP	the thermal hypersensitivity	52216
@NP	OEC transplants	52260
@NP	their ability	52293
@NP	clinical trials	52310
@VP	to regenerate following traumatic injury	154
@VP	regenerate following traumatic injury	157
@VP	Using the same injury model	798
@VP	known to stimulate the intrinsic growth response in other neurons	897
@VP	to stimulate the intrinsic growth response in other neurons	903
@VP	stimulate the intrinsic growth response in other neurons	906
@VP	will promote rubrospinal regeneration in combination with OEC transplants	964
@VP	promote rubrospinal regeneration in combination with OEC transplants	969
@VP	using the phosphodiesterase inhibitor rolipram	1092
@VP	prevented cavity formation	1145
@VP	tended to reduce the overall lesion size	1267
@VP	to reduce the overall lesion size	1274
@VP	reduce the overall lesion size	1277
@VP	lowered the thresholds for thermal sensitivity of both forepaws	1329
@VP	promoted rubrospinal regeneration through the lesion site	1443
@VP	resulted in greater numbers of OECs and axonal density within the graft	1556
@VP	enhanced rubrospinal branching and attenuated astrocytic hypertrophy	1698
@VP	enhanced rubrospinal branching	1698
@VP	branching	1719
@VP	attenuated astrocytic hypertrophy	1733
@VP	fail to regenerate following spinal cord injury in higher vertebrates	1785
@VP	to regenerate following spinal cord injury in higher vertebrates	1790
@VP	regenerate following spinal cord injury in higher vertebrates	1793
@VP	associated with myelin	2014
@VP	derived from nasal mucosa	3194
@VP	derived from the olfactory bulb	3427
@VP	see Plunet et al. , 2002	4198
@VP	stimulated expression of regeneration-associated genes	4315
@VP	was initiated 1 year after injury -LRB- Kwon et al. , 2002 -RRB-	4534
@VP	initiated 1 year after injury -LRB- Kwon et al. , 2002 -RRB-	4538
@VP	enhanced their neurite outgrowth in vitro	4800
@VP	counteracted the inhibitory environment of the injured spinal cord	5082
@VP	infused into the vicinity of the red nucleus	5631
@VP	prevents the axotomy-induced atrophy	5676
@VP	will promote regeneration of rubrospinal axons into and beyond OEC transplants	5923
@VP	promote regeneration of rubrospinal axons into and beyond OEC transplants	5928
@VP	To assess this	6098
@VP	assess this	6101
@VP	elevating cAMP level for 2 weeks	6300
@VP	to promote regeneration of rubrospinal axons through and beyond engrafted OECs	6380
@VP	promote regeneration of rubrospinal axons through and beyond engrafted OECs	6383
@VP	through and beyond engrafted OECs	6425
@VP	combined with OEC transplants	6512
@VP	increased the numbers of OECs and axonal density within the graft	6542
@VP	enhanced rubrospinal branching	6656
@VP	branching	6677
@VP	attenuated astrocytic hypertrophy rostral to the lesion site	6691
@VP	were approved by the Animal Care Committee of the University of British Columbia	6887
@VP	approved by the Animal Care Committee of the University of British Columbia	6892
@VP	expressing green fluorescent protein were sacrificed by decapitation	7193
@VP	were sacrificed by decapitation	7230
@VP	sacrificed by decapitation	7235
@VP	harvested from one pup	7468
@VP	mechanically dissociated	7492
@VP	performed using anti-Thy1.1-mediated complement lysis	8042
@VP	using anti-Thy1.1-mediated complement lysis	8052
@VP	to remove the majority of contaminating fibroblasts	8096
@VP	remove the majority of contaminating fibroblasts	8099
@VP	replated in DMEM/F -12 , 10 % FBS , and 100 U/ml P/S	8160
@VP	subjected to Thy1.1-mediated complement lysis	8287
@VP	grown in the same media for an additional 24	8337
@VP	plated onto plastic coverslips	8450
@VP	fixed for antigenic assessment at the same time	8485
@VP	collecting cells from the cultures for transplantation	8536
@VP	were assessed as at least 75 % double immunopositive for p75 and GFAP	8597
@VP	assessed as at least 75 % double immunopositive for p75 and GFAP	8602
@VP	assessed as fibronectin1/p75 --	8694
@VP	did not exceed 25 %	8725
@VP	exceed 25 %	8733
@VP	plating media , composition of plating media , and plating substrate	8787
@VP	plating media , composition of plating media	8787
@VP	plating substrate	8836
@VP	expand very poorly -LRB- Richter and Roskams , 2008 -RRB-	8930
@VP	happened to be higher than that in our previous reports	8994
@VP	to be higher than that in our previous reports	9003
@VP	be higher than that in our previous reports	9006
@VP	has previously been reported to be beneficial for axonal regeneration	9152
@VP	been reported to be beneficial for axonal regeneration	9167
@VP	reported to be beneficial for axonal regeneration	9172
@VP	to be beneficial for axonal regeneration	9181
@VP	be beneficial for axonal regeneration	9184
@VP	were plated at a density of 5,600 cells/cm2 into T75 flasks for transplantation	9382
@VP	plated at a density of 5,600 cells/cm2 into T75 flasks for transplantation	9387
@VP	using 0.25 % trypsin/1 % EDTA	9541
@VP	ranged from 11 to 14 days in vitro	9725
@VP	using freshly prepared OECs	9789
@VP	were used for this experiment	10121
@VP	used for this experiment	10126
@VP	were conducted in parallel under identical conditions	10442
@VP	conducted in parallel under identical conditions	10447
@VP	treated all groups with this drug	11049
@VP	might have had unknown synergic effects with some of the treatments	11096
@VP	have had unknown synergic effects with some of the treatments	11102
@VP	had unknown synergic effects with some of the treatments	11107
@VP	was performed on the left side , exposing the fourth and fifth cervical segments	11535
@VP	performed on the left side , exposing the fourth and fifth cervical segments	11539
@VP	exposing the fourth and fifth cervical segments	11567
@VP	to expose the dorsolateral funiculus , which includes the rubrospinal tract	11652
@VP	expose the dorsolateral funiculus , which includes the rubrospinal tract	11655
@VP	includes the rubrospinal tract	11696
@VP	grinding the blades to a width of 0.2 mm and length of 2 mm	11905
@VP	is possible to insert them to a depth of 2 mm with good accuracy	11970
@VP	to insert them to a depth of 2 mm with good accuracy	11982
@VP	insert them to a depth of 2 mm with good accuracy	11985
@VP	described previously	12370
@VP	attached to a Hamilton syringe	12532
@VP	dividing the suspension equally between these two points	12648
@VP	was injected , so that each rat received a total of 150,000 -- 180,000 cells	12739
@VP	injected , so that each rat received a total of 150,000 -- 180,000 cells	12743
@VP	received a total of 150,000	12770
@VP	received the same volume of DMEM	12829
@VP	injected at the same sites at the same rate	12868
@VP	remained in the spinal cord and were not withdrawn with the syringe	13001
@VP	remained in the spinal cord	13001
@VP	were not withdrawn with the syringe	13033
@VP	withdrawn with the syringe	13042
@VP	was slowly pulled back	13099
@VP	pulled back	13110
@VP	repositioned	13134
@VP	closed with wound clips	13161
@VP	infusing cAMP	13225
@VP	described previously	13399
@VP	treated with cAMP	13776
@VP	treated with vehicle	13944
@VP	received the vehicle solution alone	13965
@VP	was closed with wound clips	14108
@VP	closed with wound clips	14112
@VP	infusing rolipram	14156
@VP	prevents hydrolysis of cAMP and leads to accumulation of cAMP	14226
@VP	prevents hydrolysis of cAMP	14226
@VP	leads to accumulation of cAMP	14258
@VP	connected to an osmotic pump -LRB- Alzet no. 2ML1 , 10 µl/hr ; Alzet -RRB-	14401
@VP	were changed at the end of each week and removed at the end of the 14 days	14471
@VP	were changed at the end of each week	14471
@VP	changed at the end of each week	14476
@VP	removed at the end of the 14 days	14512
@VP	treated with rolipram	14555
@VP	treated with vehicle	14685
@VP	received the vehicle solution alone	14706
@VP	was closed with wound clips	14789
@VP	closed with wound clips	14793
@VP	encourages rats to use their forelimbs for vertical exploration	15018
@VP	to use their forelimbs for vertical exploration	15034
@VP	use their forelimbs for vertical exploration	15037
@VP	was placed behind the cylinder to allow scoring of movements from all viewpoints	15092
@VP	placed behind the cylinder to allow scoring of movements from all viewpoints	15096
@VP	to allow scoring of movements from all viewpoints	15123
@VP	allow scoring of movements from all viewpoints	15126
@VP	was scored frame by frame at a later time point by a blinded rater	15187
@VP	scored frame by frame at a later time point by a blinded rater	15191
@VP	contacting the wall of the cylinder during a full rear	15413
@VP	was used	15491
@VP	used	15495
@VP	To reflect a more accurate use of the left forelimb	15501
@VP	reflect a more accurate use of the left forelimb	15504
@VP	was adapted from Whishaw 's test -LRB- Whishaw et al. , 1993 -RRB-	15758
@VP	adapted from Whishaw 's test -LRB- Whishaw et al. , 1993 -RRB-	15762
@VP	scoring is described elsewhere -LRB- Chan et al. , 2005 -RRB-	15833
@VP	is described elsewhere -LRB- Chan et al. , 2005 -RRB-	15841
@VP	described elsewhere -LRB- Chan et al. , 2005 -RRB-	15844
@VP	to reach through a 1-cm opening for a food pellet placed in a dimple 2 cm away	15931
@VP	reach through a 1-cm opening for a food pellet placed in a dimple 2 cm away	15934
@VP	placed in a dimple 2 cm away	15981
@VP	walk to the back of the box after each reach and position itself for every reach	16030
@VP	reaching -LRB- score 3 -RRB-	16207
@VP	grasping -LRB- score 5 -RRB-	16227
@VP	retrieving -LRB- score 7 -RRB- a food pellet	16251
@VP	see Chan et al. , 2005	16299
@VP	To perform the food-pellet-reaching task	16323
@VP	perform the food-pellet-reaching task	16326
@VP	to prevent any influences on other behavioral tests	16368
@VP	prevent any influences on other behavioral tests	16371
@VP	were fasted once per week on the night preceding the testing day	16430
@VP	fasted once per week on the night preceding the testing day	16435
@VP	preceding the testing day	16469
@VP	to use the affected paw in a motor behavior test , e.g. , the cylinder test	16596
@VP	use the affected paw in a motor behavior test , e.g. , the cylinder test	16599
@VP	detailed elsewhere -LRB- Ramer et al. , 2004b ; Bretzner et al. , 2008 -RRB-	16700
@VP	was examined by using the plantar tester -LRB- Ugo Basile , Italy -RRB-	16799
@VP	examined by using the plantar tester -LRB- Ugo Basile , Italy -RRB-	16803
@VP	using the plantar tester -LRB- Ugo Basile , Italy -RRB-	16815
@VP	infrared source	16958
@VP	was positioned under the center of the palm of the forepaw	16974
@VP	positioned under the center of the palm of the forepaw	16978
@VP	was recorded for both forepaws	17077
@VP	recorded for both forepaws	17081
@VP	withdraw	17124
@VP	was recorded for both forepaws	17133
@VP	recorded for both forepaws	17137
@VP	to ensure a control baseline	17249
@VP	ensure a control baseline	17252
@VP	was measured before surgery	17422
@VP	measured before surgery	17426
@VP	were tested weekly for 4 weeks after injury and treatment	17467
@VP	tested weekly for 4 weeks after injury and treatment	17472
@VP	was blinded to the treatment given	17539
@VP	blinded to the treatment given	17543
@VP	given	17568
@VP	Tracing of Rubrospinal Axons	17575
@VP	tracing of rubrospinal axons	17640
@VP	placed in a Kopf stereotaxic frame	17875
@VP	was stereotaxically injected into the red nucleus at a rate of 80 nl	18023
@VP	injected into the red nucleus at a rate of 80 nl	18043
@VP	glued to a Hamilton syringe	18149
@VP	to ensure that BDA was not withdrawn with the syringe	18344
@VP	ensure that BDA was not withdrawn with the syringe	18347
@VP	was not withdrawn with the syringe	18363
@VP	withdrawn with the syringe	18371
@VP	buffered 4 %	18639
@VP	dissected	18743
@VP	postfixed in 4 % paraformaldehyde overnight	18754
@VP	cryoprotected in 24 % sucrose in 0.1 M phosphate buffer over 2 -- 3 days	18798
@VP	frozen in isopentane over dry ice	18872
@VP	were cut into 20-µm sections on a cryostat and stored at 2808C	18919
@VP	were cut into 20-µm sections on a cryostat	18919
@VP	cut into 20-µm sections on a cryostat	18924
@VP	stored at 2808C	18966
@VP	were cut into 20-µm sections in the coronal plane	19011
@VP	cut into 20-µm sections in the coronal plane	19016
@VP	were cut into 20-µm longitudinal sections in the horizontal plane	19094
@VP	cut into 20-µm longitudinal sections in the horizontal plane	19099
@VP	cutting	19167
@VP	thawed on a slide warmer for 30 min	19197
@VP	rehydrated in PBS 10 mM three times for 5 min each	19234
@VP	to prevent nonspecific binding	19363
@VP	prevent nonspecific binding	19366
@VP	were applied for 24 hr at room temperature	19806
@VP	applied for 24 hr at room temperature	19811
@VP	raised in donkey	19903
@VP	conjugated to Alexa 350 , Alexa 488 , and Cy3	19921
@VP	were applied for 2	19969
@VP	applied for 2	19974
@VP	was visualized by using Cy3	20018
@VP	visualized by using Cy3	20022
@VP	using Cy3	20036
@VP	applied for 2 -- 3 hr at room temperature	20127
@VP	were coverslipped in glycerol mounting liquid -LRB- Sigma -RRB-	20176
@VP	coverslipped in glycerol mounting liquid -LRB- Sigma -RRB-	20181
@VP	given by Verge et al.	20267
@VP	was used , with some modification	20296
@VP	used , with some modification	20300
@VP	was complementary to bases 220 -- 270 -LRB- Basi et al. , 1987 -RRB-	20523
@VP	using deoxynucleotide terminal transferase according to a standard protocol	20638
@VP	see Giehl and Tetzlaff , 1996	20882
@VP	were dipped in Kodak NTB-2 emulsion	20924
@VP	dipped in Kodak NTB-2 emulsion	20929
@VP	were exposed for 3 days for Ta1-tubulin and 7 days for GAP-43	20964
@VP	exposed for 3 days for Ta1-tubulin and 7 days for GAP-43	20969
@VP	showed no specific binding -LRB- data not shown -RRB-	21264
@VP	not shown	21297
@VP	were coded to blind the observer	21734
@VP	coded to blind the observer	21739
@VP	equally distributed between the dorsal root entry zone and the central canal	22381
@VP	were adapted from Ramer et al. -LRB- 2004b ; see Fig. 2A	22649
@VP	adapted from Ramer et al. -LRB- 2004b ; see Fig. 2A	22654
@VP	see Fig. 2A	22688
@VP	equally distributed between the dorsal root entry zone and the central canal	22848
@VP	calculating the total pixels in this area -LRB- Fig. 2B -- D -RRB-	22929
@VP	see Fig. 3	23022
@VP	branching	23045
@VP	MacDermid et al.	23158
@VP	is described below and illustrated in Supporting Information Figure 7	23237
@VP	is described below	23237
@VP	described below	23240
@VP	illustrated in Supporting Information Figure 7	23260
@VP	Supporting Information Figure 7	23275
@VP	selects all immunopositive processes regardless of their relative intensity	23501
@VP	overlying immunopositive profiles	23654
@VP	had a value of 68	23688
@VP	had a value of 0	23728
@VP	dividing the resulting pixel values by 68	23749
@VP	was generated	23818
@VP	generated	23822
@VP	was subsequently expressed as function of the window area	23854
@VP	expressed as function of the window area	23871
@VP	was in this manner converted to density measurements -LRB- for examples see Supp	23937
@VP	converted to density measurements -LRB- for examples see Supp	23956
@VP	see Supp	24004
@VP	to collect the number of pixels along this axis -LRB- Supp	24168
@VP	collect the number of pixels along this axis -LRB- Supp	24171
@VP	along this axis -LRB- Supp	24200
@VP	7D	24234
@VP	then averaged from three sections per animal	24394
@VP	averaged from each treatment group	24445
@VP	7D	24578
@VP	branching through OECs transplants -LRB- see Fig. 4 -RRB-	24648
@VP	see Fig. 4	24684
@VP	branching within the gray matter rostral	24712
@VP	will be referred to as cell profile density in the rest of this paper	24796
@VP	be referred to as cell profile density in the rest of this paper	24801
@VP	referred to as cell profile density in the rest of this paper	24804
@VP	to	24813
@VP	did not discern any changes in numbers from changes in cell size	24874
@VP	discern any changes in numbers from changes in cell size	24882
@VP	taken in the longitudinal -LRB- horizontal -RRB- plane as described above	25080
@VP	described above	25128
@VP	did not find any evidence for axonal regeneration	25156
@VP	find any evidence for axonal regeneration	25164
@VP	represents a measure of rubrospinal axon retraction -LRB- see Fig. 5A , B -RRB-	25468
@VP	see Fig. 5A , B	25521
@VP	see Fig. 5C	25847
@VP	repeated ANOVA	25892
@VP	to detect differences in the axonal or cellular density at each given distance	26121
@VP	detect differences in the axonal or cellular density at each given distance	26124
@VP	to detect differences in behavioral outcome measurements at each time point	26204
@VP	detect differences in behavioral outcome measurements at each time point	26207
@VP	were further analyzed using the post hoc Tukey - Kramer test	26470
@VP	analyzed using the post hoc Tukey	26483
@VP	using the post hoc Tukey	26492
@VP	did not fit a normal distribution	26567
@VP	fit a normal distribution	26575
@VP	ranked sum test was used , followed by a x2 test	26635
@VP	was used , followed by a x2 test	26651
@VP	used , followed by a x2 test	26655
@VP	≤ 0.05 -LRB- two-tailed -RRB- were considered significant	26707
@VP	were considered significant	26726
@VP	considered significant	26731
@VP	TABLE I.	26764
@VP	used	26855
@VP	for histological and behavioral quantifications	26860
@VP	indicates the total number of animals used for histology	26927
@VP	used for histology	26965
@VP	successfully traced with BDA	27034
@VP	used to quantify the dieback and branching of rubrospinal axons	27067
@VP	used to quantify the dieback	27067
@VP	to quantify the dieback	27072
@VP	quantify the dieback	27075
@VP	branching of rubrospinal axons	27100
@VP	infusing cAMP and OEC transplants	27180
@VP	fails to promote regeneration of rubrospinal axons	27214
@VP	to promote regeneration of rubrospinal axons	27220
@VP	promote regeneration of rubrospinal axons	27223
@VP	indicates the lesion epicenter 310	27639
@VP	bar 5 250 µm	27681
@VP	can be viewed in the online issue , which is available at wileyonlinelibrary.com	27709
@VP	be viewed in the online issue , which is available at wileyonlinelibrary.com	27713
@VP	viewed in the online issue , which is available at wileyonlinelibrary.com	27716
@VP	is available at wileyonlinelibrary.com	27750
@VP	fill the lesion and reduce cavity and glial scar formation	27805
@VP	fill the lesion	27805
@VP	reduce cavity and glial scar formation	27825
@VP	normalized on the contralateral noninjured side	27909
@VP	followed by v2 test for A , C , D , * P < 0.05 compared with vehicle-DMEM	28205
@VP	< 0.05 compared with vehicle	28277
@VP	< 0.05 compared with vehicle	28330
@VP	enhances the OEC density	28458
@VP	Note the Schwann cell-like morphology	28655
@VP	received cell body treatment	28745
@VP	received cell body treatment	28803
@VP	Note that OECs align with some thin and thick axons regardless of the treatment	29073
@VP	align with some thin and thick axons regardless of the treatment	29088
@VP	received systemic treatment with rolipram	29187
@VP	followed by x2 test	29292
@VP	= 50 µm	29366
@VP	can be viewed in the online issue , which is available at wileyonlinelibrary.com	29389
@VP	be viewed in the online issue , which is available at wileyonlinelibrary.com	29393
@VP	viewed in the online issue , which is available at wileyonlinelibrary.com	29396
@VP	is available at wileyonlinelibrary.com	29430
@VP	enhances axonal density through OEC transplants	29513
@VP	received cell body treatment	29790
@VP	received systemic treatment with rolipram	29853
@VP	followed by v2 test	29958
@VP	fail to promote regeneration	30065
@VP	to promote regeneration	30070
@VP	promote regeneration	30073
@VP	prevent retraction of rubrospinal tract axons from lesion epicenter	30098
@VP	resulting from OEC transplants	30800
@VP	received the cell body treatment -LRB- A , B -RRB- or the systemic treatment	31045
@VP	followed by x2 test	31132
@VP	compared	31224
@VP	compared with veh-DMEM ,	31256
@VP	enhances the functional recovery of the left injured forelimb	31417
@VP	followed by x2 test	31766
@VP	see Supp	32874
@VP	Reduce Cavity and Glial Scar Formation	32933
@VP	changed the behavior of OECs in the injured spinal cord	33035
@VP	surrounded by a rim of GFAPpositive hypertrophic astrocytes -LRB- Fig. 1A -RRB-	33185
@VP	are shown in Figure 1	33293
@VP	shown in Figure 1	33297
@VP	integrated well	33591
@VP	fill the lesion site , with many OECs interdigitating with the host environment	33623
@VP	interdigitating with the host environment	33660
@VP	defined by a disrupted spinal cord cytoarchitecture	33810
@VP	disrupted spinal cord cytoarchitecture	33823
@VP	appeared to reduce the size of the lesion area -LRB- Fig. 2B -RRB-	33947
@VP	to reduce the size of the lesion area -LRB- Fig. 2B -RRB-	33956
@VP	reduce the size of the lesion area -LRB- Fig. 2B -RRB-	33959
@VP	filling most of the lesion site	34013
@VP	enhance the trend of the OECs to reduce lesion area -LRB- Fig. 2B -RRB-	34490
@VP	to reduce lesion area -LRB- Fig. 2B -RRB-	34520
@VP	reduce lesion area -LRB- Fig. 2B -RRB-	34523
@VP	disrupted spinal cord cytoarchitecture	34640
@VP	defined as cross-sectional area of the GFP positive cells	34715
@VP	was not seen after cell body treatment with dbcAMP -LRB- Fig. 3C -RRB-	35162
@VP	seen after cell body treatment with dbcAMP -LRB- Fig. 3C -RRB-	35170
@VP	observed at the end of the experimental period by Ki67 immunostaining -LRB- Supp	35331
@VP	5 ; see Discussion for further details -RRB-	35419
@VP	see	35422
@VP	had a random orientation in the lesion epicenter	35663
@VP	aligned with axonal profiles of all calibers -LRB- bottom panels in Fig. 3 -RRB-	35883
@VP	have shown previously that OECs attract large numbers of host Schwann cells	35971
@VP	shown previously that OECs attract large numbers of host Schwann cells	35976
@VP	attract large numbers of host Schwann cells	36003
@VP	join these strands	36080
@VP	To stain various axonal populations	36304
@VP	stain various axonal populations	36307
@VP	used antibodies for both neurofilament 200 and bIII-tubulin	36344
@VP	-LRB- Supp	36903
@VP	stain for neurofilament 200 and bIII-tubulin	37164
@VP	traced rubrospinal axons into / through this spinal bridge of OECs	37279
@VP	to detect any rubrospinal axon growth beyond the lesion in any treatment group	37356
@VP	detect any rubrospinal axon growth beyond the lesion in any treatment group	37359
@VP	were in close association with rostral OEC grafts	37468
@VP	bridging the lesion site itself	37576
@VP	as shown in Figure 1C and in our camera lucida drawings -LRB- Supp	37609
@VP	retract following axotomy -LRB- Ye and Houle , 1997 -RRB-	38046
@VP	attenuated in all treatment groups compared with veh-DMEM -LRB- Fig. 5A , Supp	38344
@VP	anterogradely traced axons	38467
@VP	ended within the host tissue	38494
@VP	filling the injections sites -LRB- Fig. 1D , Supp	38595
@VP	have been spared	38748
@VP	been spared	38753
@VP	spared	38758
@VP	newly sprouted	38843
@VP	not shown	39173
@VP	affected the terminal branching of the RS axons within the cervical gray matter	39248
@VP	branching of the RS	39270
@VP	bypass the lesion site and thereby contribute	39414
@VP	bypass the lesion site	39414
@VP	thereby contribute	39441
@VP	labeled cross-sectioned axons in the rubrospinal tract at this level	39781
@VP	normalized axon profile index ; Fig. 5C	39851
@VP	To understand the behavioral effects of our treatments	40130
@VP	understand the behavioral effects of our treatments	40133
@VP	contributes to thermal hypersensitivity of the forepaws	40875
@VP	assessed the mechanical thresholds	40940
@VP	forepaw using the cell body treatment with cAMP -LRB- Supp	41018
@VP	have not been able to assess changes for the systemic treatment	41129
@VP	been able to assess changes for the systemic treatment	41138
@VP	to assess changes for the systemic treatment	41148
@VP	assess changes for the systemic treatment	41151
@VP	dropped to 30 -- 40 %	41659
@VP	never returned to baseline over the 4 weeks of assessment	41681
@VP	resulted in a usage of left plus both forelimbs of about 50 %	41813
@VP	reached significance at a usage level of 59 %	41949
@VP	increased the thermal hypersensitivity of the forepaws	42149
@VP	contribute to the improvement of functional recovery	42539
@VP	improved by rolipram plus OECs	42652
@VP	does not prove any causality but suggests possible links	42723
@VP	does not prove any causality	42723
@VP	prove any causality	42732
@VP	suggests possible links	42756
@VP	could allow more axons to cross the transplant -- host interface	42870
@VP	allow more axons to cross the transplant -- host interface	42876
@VP	to cross the transplant -- host interface	42893
@VP	cross the transplant -- host interface	42896
@VP	using their left forelimb more	43146
@VP	left forelimb more	43158
@VP	exhibited less GFAP immunoreactivity	43188
@VP	treated with OECs and rolipram	43419
@VP	integrated into the injured rat spinal cord	43625
@VP	filled the lesion site	43670
@VP	decreased cavitation	43694
@VP	attracting massive axonal sprouting into the injury site	43769
@VP	sprouting into the injury site	43795
@VP	reduced the axonal dieback of rubrospinal axons	43914
@VP	failed to promote their regeneration into and beyond the injury site	43966
@VP	to promote their regeneration into and beyond the injury site	43973
@VP	promote their regeneration into and beyond the injury site	43976
@VP	enhanced the density of the transplanted OECs	44060
@VP	also increased the density of axonal sprouting into the OEC transplants	44110
@VP	sprouting into the OEC transplants	44147
@VP	reaching almost twice the levels of controls	44300
@VP	infused subcutaneously via osmotic minipumps	44889
@VP	attenuated the retraction of rubrospinal axons from the injury site	44960
@VP	did not reach significance	45145
@VP	reach significance	45153
@VP	to discern the prevention of retraction/dieback from sprouting of axons	45193
@VP	discern the prevention of retraction/dieback from sprouting of axons	45196
@VP	sprouting of axons	45246
@VP	may occur in parallel	45282
@VP	occur in parallel	45286
@VP	suggest that these had been protected	45376
@VP	had been protected	45395
@VP	been protected	45399
@VP	protected	45404
@VP	had a neuroprotective effect on their axons	45483
@VP	is still frustrated	46060
@VP	can only serve as a proof of principle	46260
@VP	serve as a proof of principle	46269
@VP	alone also prevented rubrospinal axon retraction	46515
@VP	had several beneficial effects , not seen in any of the other treatment groups	46625
@VP	had several beneficial effects	46625
@VP	seen in any of the other treatment groups	46661
@VP	to switch their morphology to an astrocyte-like type within 1 day in vitro	47205
@VP	switch their morphology to an astrocyte-like type within 1 day in vitro	47208
@VP	exhibited an elongated , spindle-shape morphology	47352
@VP	elongated , spindle-shape morphology	47365
@VP	was no longer applied at this time	47546
@VP	applied at this time	47560
@VP	might have enhanced the amount of trophic factors produced	47799
@VP	have enhanced the amount of trophic factors produced	47805
@VP	enhanced the amount of trophic factors produced	47810
@VP	produced	47849
@VP	enhance axonal sprouting and sparing -LRB- Hendriks et al. , 2006 -RRB-	48117
@VP	sprouting and sparing	48132
@VP	improved recovery of left forelimb usage	48325
@VP	attenuated astrocytic hypertrophy	48392
@VP	enhanced branching of rubrospinal axons rostral to the lesion site	48430
@VP	branching of rubrospinal axons rostral to the lesion site	48439
@VP	bypass the lesion in the spared host tissue	48611
@VP	branching of the intact rubrospinal system	48793
@VP	innervated from higher cervical spinal cord levels	49064
@VP	was no recovery in the food-pellet-reaching test	49234
@VP	to promote axonal regeneration of rubrospinal neurons into cell transplants	49402
@VP	promote axonal regeneration of rubrospinal neurons into cell transplants	49405
@VP	are likely more sensitive to axotomy than dorsal root ganglia	49519
@VP	are less responsive to OECs grafts and/or that the OEC	49822
@VP	are less responsive to OECs grafts	49822
@VP	that the OEC	49864
@VP	lack critical factors or spatial alignments compared with nerve grafts	49884
@VP	left untraced , including the sensory systems	50043
@VP	suggest that the OECs alone had a tendency to lower thermal thresholds	50114
@VP	had a tendency to lower thermal thresholds	50142
@VP	was robust after the combination of OECs with rolipram	50202
@VP	could be due to a higher level of neurotrophins in the injured spinal cord	50270
@VP	be due to a higher level of neurotrophins in the injured spinal cord	50276
@VP	produce the mRNAs for these neurotrophins	50577
@VP	attract Schwann cells into the spinal cord	50733
@VP	might be elicited by LP-OECs	50924
@VP	be elicited by LP-OECs	50930
@VP	elicited by LP-OECs	50933
@VP	to attract endogenous Schwann cells previously	50989
@VP	attract endogenous Schwann cells previously	50992
@VP	might also have potentiated this sensitization of sensory neurons	51158
@VP	have potentiated this sensitization of sensory neurons	51169
@VP	potentiated this sensitization of sensory neurons	51174
@VP	is speculative	51239
@VP	might have increased the excitability of spinal interneuronal circuits	51330
@VP	have increased the excitability of spinal interneuronal circuits	51336
@VP	increased the excitability of spinal interneuronal circuits	51341
@VP	enhanced the motor performance in the cylinder test	51451
@VP	appeared to correlate with the rubrospinal branching rostral to the lesion site	51513
@VP	to correlate with the rubrospinal branching rostral to the lesion site	51522
@VP	correlate with the rubrospinal branching rostral to the lesion site	51525
@VP	resulting from the lamina propria-derived OECs	51639
@VP	using autologous cell transplants in combination with systemic rolipram infusion	51706
@VP	engrafted	51854
@VP	sprouting / sparing of rubrospinal tract axons	51973
@VP	to identify and characterize more specifically the neural mechanisms	52069
@VP	identify and characterize more specifically the neural mechanisms	52072
@VP	contributing to this functional recovery	52138
@VP	resulting from OEC transplants before assessing their ability in clinical trials	52245
@VP	assessing their ability in clinical trials	52283
